var title_f24_46_25312="M mode amyloid cardiomyopathy";
var content_f24_46_25312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of amyloid cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiogram in a patient with amyloid cardiomyopathy shows a small left ventricular (LV) cavity, brightly reflective myocardium, and markedly reduced systolic function.",
"    <div class=\"footnotes\">",
"     IVS: interventricular septum; PWLV: posterior wall of the LV.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25312=[""].join("\n");
var outline_f24_46_25312=null;
var title_f24_46_25313="Calculus deposits";
var content_f24_46_25313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calculus deposits along the gingival margin on the lingual side of the lower teeth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Heavy deposits are present on the left side, and gingivitis is more pronounced than on the right. A large carious lesion is evident on the lower left molar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Griffen, DDS, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25313=[""].join("\n");
var outline_f24_46_25313=null;
var title_f24_46_25314="Manual compression of the liver for hemostasis";
var content_f24_46_25314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manual compression of the liver for hemostasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Manual compression of the liver parenchyma is accomplished by pressing the injured surfaces firmly together.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25314=[""].join("\n");
var outline_f24_46_25314=null;
var title_f24_46_25315="Patient information: Kidney transplant (The Basics)";
var content_f24_46_25315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16440\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37809\">",
"         Kidney transplant",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"          Anatomy of the urinary tract",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/42/19107\">",
"         Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/43/16051\">",
"         Patient information: Peritoneal dialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/15/12531\">",
"         Patient information: Planning for a kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/44/35523\">",
"         Patient information: Polycystic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/22/11619\">",
"         Patient information: Preparing for hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/26/9635\">",
"         Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40852\">",
"         Patient information: Hemodialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/10/14501\">",
"         Patient information: Peritoneal dialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/24/38277\">",
"         Patient information: Polycystic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Kidney transplant (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/kidney-transplant-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16549803\">",
"      <span class=\"h1\">",
"       What is a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A kidney transplant is a surgery to insert a new, healthy kidney into a person whose kidneys are diseased (",
"      <a class=\"graphic graphic_figure graphicRef59957 \" href=\"UTD.htm?36/59/37809\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549818\">",
"      <span class=\"h1\">",
"       Why might I have a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might have a kidney transplant to treat kidney failure.",
"     </p>",
"     <p>",
"      Normally, the kidneys filter the blood and remove waste and excess salt and water (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 2",
"      </a>",
"      ). When people have kidney failure, also called &ldquo;end-stage renal disease,&rdquo; their kidneys stop working. The healthy new kidney can do the job of the diseased kidneys. (People need only 1 kidney to live.)",
"     </p>",
"     <p>",
"      Kidney failure can be treated in other ways besides a kidney transplant. But people usually benefit most from a kidney transplant. People who get a kidney transplant usually live longer and have a better quality of life than people who get other treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549833\">",
"      <span class=\"h1\">",
"       Where can a new kidney come from?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A new kidney can come from a:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Living donor &ndash; A living donor is usually a family member or friend. He or she can be related to you, but doesn&rsquo;t need to be. A living donor can also be someone you don&rsquo;t know, but this is not as common.",
"       </li>",
"       <li>",
"        Dead donor &ndash; If you don&rsquo;t have a living donor, you can get on a list to get a kidney from a dead donor. An organization called &ldquo;UNOS&rdquo; keeps this list. When a new kidney becomes available, UNOS decides who is next on the list to get it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549848\">",
"      <span class=\"h1\">",
"       What needs to happen before I can get a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you can get a kidney transplant, your doctor will send you to a transplant center. There, you will meet with doctors and have exams and tests. To get a kidney transplant, you need to meet certain conditions.",
"     </p>",
"     <p>",
"      If you have a living donor, he or she needs to go to a transplant center, too. He or she will meet with doctors and have exams and tests. Donors also need to meet certain conditions to donate a kidney. Plus, your donor&rsquo;s blood needs to match your blood.",
"     </p>",
"     <p>",
"      If you don&rsquo;t have a living donor or if he or she isn&rsquo;t a good match, you can get on the UNOS list. Your doctor can also talk with you about other ways to find a living donor.",
"     </p>",
"     <p>",
"      More information about how to plan for a kidney transplant can be found in the following topic: (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       \"Patient information: Planning for a kidney transplant (The Basics)\"",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549863\">",
"      <span class=\"h1\">",
"       What happens during a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a living donor, a doctor will remove 1 of his or her kidneys. He or she will also remove the ureter, which is the tube from the kidney to the bladder that urine flows through.",
"     </p>",
"     <p>",
"      A doctor will make an opening in your lower belly and put the new kidney in your lower belly. He or she will attach the new ureter to your bladder. A new kidney is not put in the same place as the diseased kidneys. In fact, the diseased kidneys are often left in the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549878\">",
"      <span class=\"h1\">",
"       What happens after a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After a kidney transplant, you will stay in the hospital for about 3 to 5 days. Your doctor will do exams and tests to make sure your new kidney is working correctly.",
"     </p>",
"     <p>",
"      You will need to take medicines for the rest of your life. These medicines are called &ldquo;anti-rejection medicines.&rdquo; They help your body&rsquo;s infection-fighting system accept the new kidney. Normally, the infection-fighting system helps people stay healthy by attacking objects in the body that come in from the outside (&ldquo;foreign objects&rdquo;). Anti-rejection medicines help keep your body from attacking the new kidney.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549893\">",
"      <span class=\"h1\">",
"       What problems can people have after a kidney transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, people do well after surgery. They can go to work and be active. But some people have problems after a kidney transplant. These problems can happen right after the surgery or years later. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rejection of the new kidney &ndash; Even though people take anti-rejection medicines, their body might still reject and attack the new kidney. This can happen any time after a kidney transplant. It happens less often when the new kidney is from a living donor than when the new kidney is from a dead donor.",
"       </li>",
"       <li>",
"        Side effects from the anti-rejection medicines &ndash; The medicines have short-term side effects. For example, they increase a person&rsquo;s chance of getting serious infections. They also have long-term side effects. For example, they can increase a person&rsquo;s chance of getting certain types of cancer.",
"       </li>",
"       <li>",
"        High blood pressure or heart disease",
"       </li>",
"       <li>",
"        Diabetes (high blood sugar, also called &ldquo;diabetes mellitus&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549908\">",
"      <span class=\"h1\">",
"       What happens if I don&rsquo;t take my anti-rejection medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you don&rsquo;t take your anti-rejection medicines, your body will reject your new kidney and attack it. This will cause your new kidney to stop working.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16549923\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       Patient information: Planning for a kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"       Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=see_link\">",
"       Patient information: Polycystic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       Patient information: Preparing for hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"       Patient information: Peritoneal dialysis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=see_link\">",
"       Patient information: Polycystic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       Patient information: Peritoneal dialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       Patient information: Hemodialysis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/46/25315?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16440 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-218.28.111.102-3C51B1EE61-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25315=[""].join("\n");
var outline_f24_46_25315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549803\">",
"      What is a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549818\">",
"      Why might I have a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549833\">",
"      Where can a new kidney come from?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549848\">",
"      What needs to happen before I can get a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549863\">",
"      What happens during a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549878\">",
"      What happens after a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549893\">",
"      What problems can people have after a kidney transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549908\">",
"      What happens if I don&rsquo;t take my anti-rejection medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16549923\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37809\">",
"      Kidney transplant",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"       Anatomy of the urinary tract",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=related_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_46_25316="Acarbose: Pediatric drug information";
var content_f24_46_25316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acarbose: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"    see \"Acarbose: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/14/27876?source=see_link\">",
"    see \"Acarbose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Precose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Glucobay&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Alpha-glucosidase Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"      see \"Acarbose: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: Dosage must be individualized on the basis of effectiveness and tolerance; do not exceed the maximum recommended dose (use slow titration to prevent or minimize GI effects):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 25 mg 3 times/day; increase in 25 mg/day increments in 2-4 week intervals to maximum dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &le;60 kg: 50 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &gt;60 kg: 100 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Precose&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with first bite of each main meal",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type II diabetes mellitus (noninsulin-dependent, NIDDM) when hyperglycemia cannot be managed by diet alone; may be used concomitantly with metformin, a sulfonylurea, or insulin to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Precose&reg; may be confused with PreCare&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Precose&reg; [U.S., Malaysia] may be confused with Precosa brand name for",
"       <i>",
"        Saccharomyces boulardii",
"       </i>",
"       [Finland, Sweden]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F129176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea and abdominal pain tend to return to pretreatment levels over time; frequency and intensity of flatulence tend to abate with time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Edema, erythema, exanthema, hepatitis, ileus/subileus, jaundice, liver damage, pneumatosis cystoides intestinalis, rash, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acarbose or any component; diabetic ketoacidosis; cirrhosis; patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or patients predisposed to intestinal obstruction; patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption; patients who have conditions that may deteriorate as a result of increased gas formation in the intestine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia may occur when used in combination with sulfonylureas or insulin; oral glucose (absorption is not affected by acarbose) should be used instead of sucrose (table sugar) for the treatment of mild to moderate hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose-related elevations in serum transaminases occurred in 15% of acarbose-treated patients in long-term studies; these elevations were asymptomatic, reversible, more common in females, and not associated with other evidence of liver dysfunction; acarbose serum levels are proportionately higher in patients with renal dysfunction (S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2 mg/dL); until long term clinical studies are completed, use in renally-compromised patients is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Acarbose may decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neomycin: May enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been reported in animal reproduction studies; therefore, acarbose is classified as pregnancy category B. Low amounts of acarbose are absorbed systemically which should limit fetal exposure. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Acarbose has been studied for its potential role in treating GDM; however, only limited information is available describing pregnancy outcomes. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fasting blood glucose; hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ; liver enzymes every 3 months for the first year of therapy and periodically thereafter",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Target range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Blood glucose: Fasting and preprandial: 80-120 mg/dL; bedtime: 100-140 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glycosylated hemoglobin (hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ): &lt;7%",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of pancreatic &alpha;-glucosidases, resulting in delayed hydrolysis of ingested complex carbohydrates and disaccharides and absorption of glucose; dose-dependent reduction in postprandial serum insulin and glucose peaks; inhibits the metabolism of sucrose to glucose and fructose",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Average decrease in fasting blood sugar: 20-30 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;2% absorbed as active drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized exclusively within the GI tract, principally by intestinal bacteria and by digestive enzymes; 13 metabolites have been identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Low systemic bioavailability of parent compound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Fraction absorbed as intact drug is almost completely excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acarbose has been used successfully to treat postprandial hypoglycemia in children with Nissen fundoplications. Six children (4-25 months) initially received 12.5 mg before each bolus feeding of formula containing complex carbohydrates. The dosage was increased in 12.5 mg increments (dosage range: 12.5-50 mg per dose) until postprandial serum glucose was stable &ge;60 mg/dL. Most commonly reported side effects were flatulence, abdominal distension, and diarrhea (Ng, 2001).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/46/25316/abstract-text/10454950/pubmed\" id=\"10454950\" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng DD, Ferry RJ Jr, Kelly A, et al, &ldquo;Acarbose Treatment of Postprandial Hypoglycemia in Children After Nissen Fundoplication,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(6):877-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/46/25316/abstract-text/11743518/pubmed\" id=\"11743518\" target=\"_blank\">",
"        11743518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13198 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25316=[""].join("\n");
var outline_f24_46_25316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129130\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056173\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056168\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129109\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129094\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056177\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056176\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129178\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129176\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056181\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056167\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056166\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129103\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129105\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129119\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056172\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056175\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056165\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056179\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056180\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056182\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=related_link\">",
"      Acarbose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/14/27876?source=related_link\">",
"      Acarbose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_46_25317="Atrial tachycardia foci";
var content_f24_46_25317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    A schematic representation of the anatomic distribution of focal atrial tachycardias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The atrioventricular valvular annuli have been removed.",
"    <div class=\"footnotes\">",
"     %: percent; CS: coronary sinus; CT: crista terminalis; LA: left atrium; LAA: left atrial appendage; MA: mitral annulus; PV: pulmonary vein; RA: right atrium; RAA: right atrial appendage; TA: tricuspid annulus.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kistler, PM, Roberts-Thomson, KC, Haqqani, HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol 2006; 48:1010. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25317=[""].join("\n");
var outline_f24_46_25317=null;
var title_f24_46_25318="CT pyelograms ureter and renal pelvis tumors";
var content_f24_46_25318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    CT pyelograms showing tumor involving the ureters and the renal pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT pyelograms showing tumor involving the ureters (panel A) and the renal pelvis (panel B). The tumor is depicted by the arrows in each.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Jerome P Richie.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25318=[""].join("\n");
var outline_f24_46_25318=null;
var title_f24_46_25319="Use of gold compounds in rheumatic diseases";
var content_f24_46_25319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of gold compounds in rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25319/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25319/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25319/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25319/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25319/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/46/25319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forestier pioneered the use of gold for the treatment of rheumatoid arthritis (RA) in 1929 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent controlled studies confirmed the effectiveness of gold in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Gold has also been used in some patients with psoriatic arthritis, ankylosing spondylitis with polyarthritis, and juvenile idiopathic arthritis.",
"   </p>",
"   <p>",
"    The use of gold has declined since 1990; this is due to the increasing popularity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    because of convenient oral use and good long-term tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/6\">",
"     6",
"    </a>",
"    ]. Moreover, the use of conventional disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate have become complementary to the newer biologics of the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/7\">",
"     7",
"    </a>",
"    ], and their use should always precede a consideration of the introduction of an expensive biologic. It is also noteworthy that tumor necrosis factor inhibitors are well tolerated and efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetics and use of gold in the treatment of RA and other rheumatic diseases is presented in this topic review. Toxicity of gold therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link\">",
"     \"Major side effects of gold\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the use of gold requires knowledge of the different compounds available and of the drug's pharmacokinetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gold compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold compounds occur in several oxidation states, with only complex gold compounds being used (",
"    <a class=\"graphic graphic_figure graphicRef58824 \" href=\"UTD.htm?4/50/4910\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of gold preparations are administered only by intramuscular injection:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/15/41204?source=see_link\">",
"       gold sodium thiomalate",
"      </a>",
"      (GSTM [dissolved in water], trade name Myochrysine or Myocrisin); and gold sodium thioglucose (GSTG, Solganal [dissolved in sesame oil]), gold thiopropanolsulphonate (Allochrysine), gold thiosulphate (Sanochrysin), and gold 4-amino-2-mercaptobenzoic acid (Krysolgan) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/9\">",
"       9",
"      </a>",
"      ]. GSTG, although preferred by some because of lesser toxicity is currently unavailable due to discontinuation of manufacture by the producer.",
"     </li>",
"     <li>",
"      An oral gold compound,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"       auranofin",
"      </a>",
"      (Ridaura), is also available. It is a triethylphosphine gold compound that contains 29 percent gold by weight [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive clinical experience and an abundance of experimental data, the mechanism of action of gold in RA and other disorders remains uncertain. The ability of gold compounds to dissociated antigenic peptides from HLA-class II antigen presenting molecules, demonstrated, in vitro for HLA-DRB1, may be relevant, given the significant association between HLS-DR genotype and RA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .) Recent experimental evidence also suggests that GSTM acts to block PGE2 and other pro-inflammatory genes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/12\">",
"     12",
"    </a>",
"    ]. And in a collagen-induced arthritis model in rats, nanogold showed anti angiogenic and anti inflammatory activities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;After intramuscular injection, gold salts are rapidly absorbed with maximal plasma levels at two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/9\">",
"     9",
"    </a>",
"    ]. Gold levels gradually rise with treatment until a plateau is reached after six to eight weeks (",
"    <a class=\"graphic graphic_figure graphicRef56558 \" href=\"UTD.htm?5/32/5646\">",
"     figure 2",
"    </a>",
"    ). The serum gold concentration correlates with the dose of gold administered; maintenance doses of 50 mg every four weeks result in a serum concentration ranging from 75 to 125",
"    <span class=\"nowrap\">",
"     &micro;g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Approximately",
"    40 percent of the dose of intramuscular gold is eliminated, either in the urine (70 percent) or in the feces (30 percent). Intramuscular gold is retained in the body to a greater degree than oral gold. As an example, about 300 mg of elemental gold is retained following 20 weekly injections of 50 mg, while only 73 mg of gold is retained after 20 weeks of oral gold doses of 6 mg per day. The kidneys, adrenals, and reticuloendothelial system achieve the highest gold concentrations. Intracellularly, gold attaches to organelle membranes in the nuclear, mitochondrial, and lysosomal fractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION IN RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold is best used for early, nonerosive, progressive, polyarticular RA. We have also found it effective in controlling monoarticular or pauciarticular RA. The use of gold should be based on a solid diagnosis since other causes of polyarthritis, such as systemic lupus erythematosus (SLE), are aggravated by its use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/3\">",
"     3",
"    </a>",
"    ]. Gold is generally",
"    <strong>",
"     not",
"    </strong>",
"    indicated for advanced RA unless active synovitis is present.",
"   </p>",
"   <p>",
"    Gold compounds can also be given to patients with RA and complicating Felty's syndrome, Sj&ouml;gren's syndrome, preexisting neutropenia, or eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The chronic anemia, neutropenia and splenomegaly of RA may actually improve with gold therapy. In the largest reported series, a good hematologic response was noted in 60 percent of patients and a partial response occurred in 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug therapy in Felty's syndrome\", section on 'Gold'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preexisting proteinuria and dermatitis are relative contraindications to the administration of gold, since these conditions also represent potential side effects of gold. However, nonprogressive proteinuria or benign hematuria without renal failure does not preclude the use of gold in appropriate patients.",
"   </p>",
"   <p>",
"    Parenteral therapy does not appear to affect babies born to mothers treated with gold. Nevertheless, any newborn exposed to maternal gold during pregnancy or lactation should be closely monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Efficacy in RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of gold treatment in RA has been well documented over the past 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/2-5,10,14,18\">",
"     2-5,10,14,18",
"    </a>",
"    ]. The response to chrysotherapy is unaffected by patient age, sex, race, extraarticular features of RA, erythrocyte sedimentation rate (ESR), or rheumatoid factor titer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several issues have been addressed when evaluating the effect of gold in RA including efficacy when given alone, intramuscular versus oral gold, long-term benefit, gold versus other drugs, and the use of combination therapy.",
"   </p>",
"   <p>",
"    Two studies can be used to illustrate the efficacy of intramuscular gold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One double-blind, randomized trial evaluated 27 patients who had RA for less than five years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/5\">",
"       5",
"      </a>",
"      ]. These patients were followed for 30 months during a standard course and then maintenance therapy with GSTM; they were compared to group of patients treated with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/5\">",
"       5",
"      </a>",
"      ]. The patients treated with GSTM had a better outcome; this benefit required",
"      <strong>",
"       at least three months",
"      </strong>",
"      and sometimes as long as nine months to become apparent (",
"      <a class=\"graphic graphic_figure graphicRef69559 \" href=\"UTD.htm?23/19/23869\">",
"       figure 3",
"      </a>",
"      ). The positive effects were maintained for a mean of 28 months. Serial radiographs of the hands and wrists revealed fewer bone erosions in the gold treated group.",
"     </li>",
"     <li>",
"      A subsequent study using quantitative radiography found joint erosion repair in 23 percent of 29 patients with RA who were treated with GSTM and followed for 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/19\">",
"       19",
"      </a>",
"      ]. These patients had more erosion repair and less erosion progression than a comparison group of 34 patients with RA of similar duration who were not treated with gold.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Efficacy of different gold preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of oral gold in RA is inconclusive. In one study, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    , the only oral gold preparation, was evaluated in 90 patients with RA who were randomized to receive auranofin, GSTM, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/20\">",
"     20",
"    </a>",
"    ]. Follow-up over three years showed clinical improvement by articular index, grip strength, and morning stiffness in both gold treatment groups; however, lack of benefit leading to cessation of therapy was more common with auranofin (14 versus 1 with GSTM) but less common than with placebo (14 versus 27). These clinical benefits were not confirmed by the hand radiograph erosion score which showed deterioration in 75 to 80 percent in all three groups (",
"    <a class=\"graphic graphic_figure graphicRef60267 \" href=\"UTD.htm?29/4/29774\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A second report compared GSTM and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    use in 120 patients with RA over one year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/21\">",
"     21",
"    </a>",
"    ]. More patients in the auranofin group dropped out because of lack of effect, while more patients dropped out in the GSTM group due to drug toxicity (",
"    <a class=\"graphic graphic_table graphicRef73096 \" href=\"UTD.htm?36/48/37644\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    By comparison, a third report found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31476?source=see_link\">",
"     auranofin",
"    </a>",
"    was beneficial in those with early disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/22\">",
"     22",
"    </a>",
"    ]. Among 138 patients with early RA, there was significant improvement at 24 months in measures of joint swelling, disability and discomfort, and radiological progression was significantly retarded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold was once considered a mainstay in the treatment of RA. Although most studies are in agreement about its short term efficacy, the role of gold in altering the long term course of RA remains controversial. As illustrated above, for example, erosions may progress despite symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One comparative study evaluated the effect of long-term treatment of RA with sulphasalazine, gold, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ; 92 percent of patients were no longer taking gold after five years, and the median time to treatment termination was 6 to 7 months (",
"      <a class=\"graphic graphic_figure graphicRef80925 \" href=\"UTD.htm?26/12/26830\">",
"       figure 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long term efficacy of parenteral gold was also found to be lacking in a study that measured change in function using the Health Assessment Questionnaire (HAQ) and change in the number of painful joints [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/24\">",
"       24",
"      </a>",
"      ]. Among 822 patients with RA, those treated with gold for at least two years showed no significant difference in outcome compared to those who did not receive such therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, other reports suggesting long-term benefit from gold therapy. One study, for example, found that almost 30 percent of patients taking gold as initial second-line treatment for RA continued to show benefit after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/25\">",
"     25",
"    </a>",
"    ]. Another series of 98 patients with RA found significant improvement in all outcome measures (occurring in 43 to 72 percent of patients for parameters such as joint count, morning stiffness,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose, erythrocyte sedimentation rate, and overall disability) at one year despite a dropout rate of 36 percent (",
"    <a class=\"graphic graphic_figure graphicRef56178 \" href=\"UTD.htm?3/10/3247\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parenteral gold may be more likely to produce sustained improvement if used early in the course of disease; this is supported by the results of one prospective study of 440 patients with RA in which only the cohort receiving gold therapy within the first two years of disease had improved functional status that persisted for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who worsen while receiving monthly maintenance gold injections frequently benefit from a return to weekly treatment. As an example, one retrospective study of 24 patients who underwent 25 retreatments with gold found that every patient had improvement (5 fair, 19 good, 1 excellent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence that gold may have a favorable impact on the increase in mortality associated with RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\"",
"    </a>",
"    .) One retrospective analysis evaluated 573 patients over a 23 to 28 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/30\">",
"     30",
"    </a>",
"    ]. Premature deaths were prevented and survival was higher in those treated with gold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gold versus other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold has been compared to other agents used in the treatment of RA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two six-month controlled trials compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      with GSTM and placebo in 90 patients with active RA; there was equal short-term benefit with both drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 12 month prospective trial, 174 patients with early erosive RA were randomly assigned to receive either parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      or intramuscular gold; the clinical and laboratory responses were similar [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/32\">",
"       32",
"      </a>",
"      ]. The rate of radiographic progression was decreased to a similar degree by both agents and there was no significant difference in damage at six or twelve-months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/33\">",
"       33",
"      </a>",
"      ]. While the gold-treated group had somewhat better radiographic results at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/34\">",
"       34",
"      </a>",
"      ]; after six years of follow up, paradoxically, those who had discontinued gold due to adverse side-effects had a similar degree of improvement as those who continued to receive gold or methotrexate [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gold and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      have similar efficacy for patients with psoriatic arthritis. This was illustrated in a retrospective review of patients treated with gold salts or methotrexate [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/36\">",
"       36",
"      </a>",
"      ]; both were effective for this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of psoriatic arthritis\", section on 'Second-line therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gold combined with other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of long-term efficacy has led to interest in combinations of second-line agents for the treatment of RA. A formal review of the literature between 1966 and 1989 found only three prospective studies of sufficient quality to yield strong or moderately strong evidence. None of these studies conclusively demonstrated a benefit of drug combinations; two suggested a benefit, while two suggested an increase in toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective, randomized, placebo controlled study compared a combination of parenteral gold and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (52 patients) to gold plus placebo (49 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/38\">",
"     38",
"    </a>",
"    ]. The combination group showed more rapid improvement and better overall reduction of disease activity after 12 months of therapy (",
"    <a class=\"graphic graphic_figure graphicRef82675 \" href=\"UTD.htm?36/18/37165\">",
"     figure 7",
"    </a>",
"    ). This observation is similar to the short-term benefits seen in earlier single drug comparisons.",
"   </p>",
"   <p>",
"    Although the combination of gold and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been used in practice, there are few controlled trials evaluating this regimen. In the METGO study, 65 patients with RA and a partial response to methotrexate (mean dose of 18.5",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    continued methotrexate and were randomly assigned to receive GSTG (up to 50 mg per week) or placebo injections for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/39\">",
"     39",
"    </a>",
"    ]. At the end of the trial, those who received gold injections did significantly better that the placebo group; ACR20 responses occurred in 61 versus 30 percent, respectively; more withdrawals in the placebo group than the gold plus methotrexate group were due to lack of efficacy (10 of 14 versus 3 of 9, respectively); and withdrawals due to adverse events were similar in both groups (3 versus 10 percent). Mucocutaneous side effects occurred in 17 of 38",
"    <span class=\"nowrap\">",
"     gold/methotrexate",
"    </span>",
"    treated patients, leading to temporary suspension of therapy with gold. However, in 15 of 17 patients gold was reintroduced without recurrent rash or mucositis.",
"   </p>",
"   <p>",
"    In addition, a pilot study reported encouraging results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    combined with either gold or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent short term intramuscular depot injections of glucocorticoids, given in conjunction with chrysotherapy, have been advocated as an approach that can enhance the efficacy of gold while decreasing toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/41\">",
"     41",
"    </a>",
"    ]. In one report of 60 patients, for example, those randomized to pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    plus gold at the beginning were more likely to respond (57 versus 27 percent) and had less long-term disability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/42\">",
"     42",
"    </a>",
"    ]. Oral pulse glucocorticoids, however, are not as effective for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Determinants of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variable response to gold has led to attempts to identify possible determinants of efficacy. Immunogenetic data suggests that HLA phenotypes may be one factor that influences the response to gold therapy. One study, for example, found that patients possessing human leukocyte antigen HLA-DR3 were more responsive to parenteral gold than patients without DR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients with DR3 also appear more likely to develop rashes and proteinuria.",
"   </p>",
"   <p>",
"    The efficacy of gold therapy does not appear to correlate with gold toxicity. However, a treatment response has often been seen after onset of a rash [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about duration of gold therapy are empirical. In our view, gold should be continued",
"    <strong>",
"     indefinitely",
"    </strong>",
"    in patients who have an acceptable response. A separate issue is when it can be assumed that the patient is unresponsive to gold. Six months may be too short to obtain maximum benefit from chrysotherapy; thus, treatment should be extended to at least 18 months before stopping therapy because of gold-resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/5,45\">",
"     5,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Use of gold in other rheumatic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gold may also be useful in the treatment of other rheumatic disorders, including discoid lupus, juvenile chronic arthritis, psoriatic arthritis, and palindromic rheumatism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/9\">",
"     9",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DOSAGE SCHEDULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intramuscular gold dosage schedule was derived empirically from clinical experience. The current standard gold schedule for adults with RA is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Test doses of 10 mg and 25 mg are given 1 week apart.",
"     </li>",
"     <li>",
"      A 50 mg dose is given weekly until the cumulative dose totals 1 g, toxicity occurs, or there is major clinical improvement. There are many variations in this schedule, such as weekly injections of 25 mg rather than 50 mg of gold compound. Others recommend 50 mg until a cumulative total 500 to 700 mg is attained, at which time the dose is reduced to 25 mg weekly. Weekly doses above 50 mg may be more effective, but are also associated with a greater risk for toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many clinicians stop gold after 1000 mg in unresponsive cases, whereas others give an additional 10 to 20 injections of 50 mg, hoping that higher doses will work better.",
"     </li>",
"     <li>",
"      Maintenance therapy of 25 to 50 mg every two to four weeks is advocated after the initial course. In some instances, even lower maintenance doses (eg, less than 20",
"      <span class=\"nowrap\">",
"       mg/per",
"      </span>",
"      month) may suffice in patients who show substantial clinical improvement but develop mucocutaneous complications [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/46\">",
"       46",
"      </a>",
"      ]. In this report, gold was discontinued until the side effects resolved and then restarted at a 50 percent lower dose; this approach was continued until a dose that did not produce toxicity was achieved. Dosage adjustment decisions should always be based on the presence or absence of joint inflammation.",
"     </li>",
"     <li>",
"      Stopping gold after remission does not appear to increase the probability that a second or third course will be ineffective. In one report, for example, 20 of 21 patients who showed marked improvement to a first course of gold had a similar response to a second course [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25319/abstract/47\">",
"       47",
"      </a>",
"      ]. Three patients who received three courses responded to each course.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458664497\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Duncan A Gordon, MD (deceased), who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/1\">",
"      Forestier, J. Rheumatoid arthritis and its treatment by gold salts. J Lab Clin Med 1935; 20:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/2\">",
"      Hartfall, SJ, Garland, HG, Goldie, W. Gold treatment of arthritis: A review of 900 cases. Lancet 1937; 233:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/3\">",
"      Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Final report of a multicentre controlled trial. Ann Rheum Dis 1961; 20:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/4\">",
"      A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973; 16:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/5\">",
"      Sigler JW, Bluhm GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med 1974; 80:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/6\">",
"      Hurst S, Kallan MJ, Wolfe FJ, et al. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002; 29:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/7\">",
"      Rau R. Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin Rheumatol 2005; 24:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/8\">",
"      O'Dell JR, Petersen K, Leff R, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 2006; 33:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/9\">",
"      Jones G, Brooks PM. Injectable gold compounds: an overview. Br J Rheumatol 1996; 35:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/10\">",
"      Abruzzo JL. Auranofin: a new drug for rheumatoid arthritis. Ann Intern Med 1986; 105:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/11\">",
"      De Wall SL, Painter C, Stone JD, et al. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol 2006; 2:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/12\">",
"      Stuhlmeier KM. The anti-rheumatic gold salt aurothiomalate suppresses interleukin-1beta-induced hyaluronan accumulation by blocking HAS1 transcription and by acting as a COX-2 transcriptional repressor. J Biol Chem 2007; 282:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/13\">",
"      Tsai CY, Shiau AL, Chen SY, et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum 2007; 56:544.",
"     </a>",
"    </li>",
"    <li>",
"     Gordon, DA. Gold compounds. In. Textbook of Rheumatology, 5th ed, Kelley, WN, Harris, ED, Ruddy, S, Sledge, CB (Eds). WB Saunders, Philadelphia, 1997, pp. 759-769.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/15\">",
"      Dillon AM, Luthra HS, Conn DL, Ferguson RH. Parenteral gold therapy in the Felty syndrome. Experience with 20 patients. Medicine (Baltimore) 1986; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/16\">",
"      Almoallim H, Klinkhoff A. Longterm outcome of treatment of Felty's syndrome with intramuscular gold: case reports and recommendations for management. J Rheumatol 2005; 32:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/17\">",
"      Almarzouqi M, Scarsbrook D, Klinkhoff A. Gold therapy in women planning pregnancy: outcomes in one center. J Rheumatol 2007; 34:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/18\">",
"      Munro R, Hampson R, McEntegart A, et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998; 57:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/19\">",
"      Buckland-Wright JC, Clarke GS, Chikanza IC, Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 1993; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/20\">",
"      Capell HA, Lewis D, Carey J. A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis 1986; 45:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/21\">",
"      Davis P, Menard H, Thompson J, et al. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. J Rheumatol 1985; 12:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/22\">",
"      Borg G, Allander E, Lund B, et al. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J Rheumatol 1988; 15:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/23\">",
"      Situnayake RD, Grindulis KA, McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/24\">",
"      Epstein WV, Henke CJ, Yelin EH, Katz PP. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 1991; 114:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/25\">",
"      Ferraccioli GF, Salaffi F, Nervetti A, Manganelli P. Long-term outcome with gold thiosulphate and tiopronin in 200 rheumatoid patients. Clin Exp Rheumatol 1989; 7:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/26\">",
"      Wolfe F, Hawley DJ, Cathey MA. Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy. J Rheumatol 1993; 20:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/27\">",
"      Wolfe F. The curious case of intramuscular gold. Rheum Dis Clin North Am 1993; 19:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/28\">",
"      Harth M. Gold in rheumatoid arthritis: standard, substitute or sham? J Rheumatol 1993; 20:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/29\">",
"      Sagransky DM, Greenwald RA. Efficacy and toxicity of retreatment with gold salts: a retrospective review of 25 cases. J Rheumatol 1980; 7:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/30\">",
"      Lehtinen K, Isom&auml;ki H. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 1991; 18:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/31\">",
"      Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983; 287:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/32\">",
"      Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997; 36:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/33\">",
"      Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998; 37:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/34\">",
"      Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002; 41:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/35\">",
"      Sander O, Herborn G, Bock E, Rau R. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Ann Rheum Dis 1999; 58:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/36\">",
"      Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000; 27:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/37\">",
"      Boers M, Ramsden M. Long acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991; 18:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/38\">",
"      Scott DL, Dawes PT, Tunn E, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol 1989; 28:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/39\">",
"      Lehman AJ, Esdaile JM, Klinkhoff AV, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005; 52:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/40\">",
"      Bensen W, Tugwell P, Roberts RM, et al. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994; 21:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/41\">",
"      Heath MJ. Measurement of 'free' gold in patients receiving disodium aurothiomalate and the association of high free to total gold levels with toxicity. Ann Rheum Dis 1988; 47:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/42\">",
"      Heytman M, Ahern MJ, Smith MD, Roberts-Thomson PJ. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. J Rheumatol 1994; 21:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/43\">",
"      Speerstra F, van Riel PL, Reekers P, et al. The influence of HLA phenotypes on the response to parenteral gold in rheumatoid arthritis. Tissue Antigens 1986; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/44\">",
"      Fremont-Smith P, Fremont-Smith K. Association between gold induced skin rash and remission in patients with rheumatoid arthritis. Ann Rheum Dis 1990; 49:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/45\">",
"      Srinivasan R, Miller BL, Paulus HE. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum 1979; 22:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/46\">",
"      Klinkhoff AV, Teufel A. How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. J Rheumatol 1995; 22:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25319/abstract/47\">",
"      Klinkhoff AV, Teufel A. The second course of gold. J Rheumatol 1995; 22:1655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7506 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25319=[""].join("\n");
var outline_f24_46_25319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gold compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATIENT SELECTION IN RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Efficacy in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Efficacy of different gold preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long term efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gold versus other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gold combined with other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Determinants of efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Use of gold in other rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DOSAGE SCHEDULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458664497\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7506|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/50/4910\" title=\"figure 1\">",
"      Gold compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/32/5646\" title=\"figure 2\">",
"      Whole blood gold concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/19/23869\" title=\"figure 3\">",
"      Gold improves synovitis in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/4/29774\" title=\"figure 4\">",
"      Gold vs auranofin in RA I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/12/26830\" title=\"figure 5\">",
"      Termination of Rx in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/10/3247\" title=\"figure 6\">",
"      Clinical response to gold RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/18/37165\" title=\"figure 7\">",
"      Gold plus hydroxychloroquine RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7506|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/48/37644\" title=\"table 1\">",
"      Gold vs auranofin in RA II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_46_25320="Overview of diplopia";
var content_f24_46_25320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of diplopia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25320/contributors\">",
"     Don C Bienfang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25320/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25320/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/46/25320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the extraocular muscles may be the result of an abnormality of the muscle itself or an abnormality of the motor nerve to the muscle. The major symptom associated with this dysfunction is diplopia. The evaluation of neuromuscular diplopia is reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three pairs of extraocular muscles move each eye in three directions: vertically (superior and inferior), horizontally (medial and lateral), and torsionally (intorsion when the eye rotates toward the patient's nose and extorsion when the eye rotates toward the patient's shoulder). The following muscles are responsible for these movements (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"UTD.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75770 \" href=\"UTD.htm?1/37/1620\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58849 \" href=\"UTD.htm?43/36/44609\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superior rectus and inferior oblique muscles are responsible for upward vertical movements. The superior rectus acts in all fields of gaze and the inferior oblique on medial gaze.",
"     </li>",
"     <li>",
"      The inferior rectus and superior oblique muscles are responsible for downward vertical movement. The inferior rectus acts in all fields of gaze, and the superior oblique on medial gaze.",
"     </li>",
"     <li>",
"      The lateral rectus is responsible for abduction.",
"     </li>",
"     <li>",
"      The medial rectus is responsible for adduction.",
"     </li>",
"     <li>",
"      The superior oblique is responsible for intorsion.",
"     </li>",
"     <li>",
"      The inferior oblique is responsible for extorsion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The superior oblique muscle is innervated by cranial nerve IV, the lateral rectus muscle by cranial nerve VI, and all others by cranial nerve III (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"UTD.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Details of the neurologic examination with regard to eye movements are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRESENTATION/HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diplopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Be sure to determine that the diplopia is present only with both eyes open and absent when either eye is closed (binocular diplopia). Binocular diplopia suggests that the underlying problem is due to ocular misalignment; generally, patients will choose to close the eye with the dysfunctional muscle unless that is the eye with much better vision. Monocular diplopia (persists with one eye closed) suggests local eye disease or refractive error; this is generally a problem that should be referred to an ophthalmologist and is not discussed further here. Triple vision or triplopia is a rare complaint in patients with extraocular paresis, usually as a transient phenomenon in patients with superimposed nystagmus or oscillopsia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/1\">",
"     1",
"    </a>",
"    ]. Multiple images with one or both eyes is also a common complaint in patients with nuclear sclerotic cataract.",
"   </p>",
"   <p>",
"    Important questions to ask the patient with binocular diplopia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In which field of gaze is the double vision worst? The worst position of gaze represents the field of action of a paretic muscle (eg, with a right lateral rectus palsy, diplopia is greatest on right lateral gaze). If a muscle is restricted however, as in thyroid disease, the double vision is worst when trying to stretch the muscle, that is, opposite to its field of action. Thus, a patient with thyroid ophthalmopathy cannot look up because the inferior rectus is tight, not because the superior rectus is weak.",
"     </li>",
"     <li>",
"      In which field of gaze are the double images closest together?",
"     </li>",
"     <li>",
"      Is the separation of images vertical, horizontal, or oblique?",
"     </li>",
"     <li>",
"      Is there any corrective head position that makes the double vision tolerable?",
"     </li>",
"     <li>",
"      Is the double vision worse at a distance (typical of a sixth nerve palsy) or is it worse at near (typical of a medial rectus palsy)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients lack diplopia despite obvious ocular misalignment. There may be a number of explanations for this finding:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vision may be suppressed in one eye because of an old strabismus. Some patients with strabismus can develop a type of peripheral double vision if they have anomalous retinal correspondence, which is then followed by the original angle of the double vision changing because of neuromuscular disease or a change in the angle of the strabismus with age.",
"     </li>",
"     <li>",
"      Patients may have decreased vision in one eye, in which case the double vision will only be for objects large enough to see by the eye with poor vision.",
"     </li>",
"     <li>",
"      Some patients have such a wide separation of the images that they are able to ignore one of the images because it is far out of alignment with the true straight-ahead image.",
"     </li>",
"     <li>",
"      Some patients have such a minimal separation of the images that they cannot appreciate that they are seeing two images. They complain, instead, of \"blurred vision\", which is really a combination of two images.",
"     </li>",
"     <li>",
"      Some patients will have a misalignment only when the eyes are moving. However, vision is suppressed when the eyes are moving so that they are not aware of a double vision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the patient about the presence or absence of any ocular, orbital, or periorbital pain and request that the patient point to the location of the pain. Painful ophthalmoplegia has a specific differential diagnosis that is distinct from painless ophthalmoplegia (",
"    <a class=\"graphic graphic_table graphicRef77825 \" href=\"UTD.htm?3/54/3949\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse intracranial pathology is suggested by complaints of a generalized headache or pain in the area of the temple. In contrast, it is most likely that the patient has an isolated lesion of one of the cranial nerves if the pain is localized to the area just above the eyebrow on the side of the weak muscle.",
"     </li>",
"     <li>",
"      Intraorbital pathology should be considered in patients with pain localized directly to the eye.",
"     </li>",
"     <li>",
"      Sudden onset of head pain described as the worst ever experienced should be a cause for concern and suggests an intracranial aneurysm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another worrisome type of pain is one that is severe, requires heavy opiate-type medication, and is distributed to the area of the first or second division of the fifth cranial nerve. It is important in such cases to carefully test for sensory loss in the area of the forehead and cheek; such a symptom often indicates that there is a tumor pressing on the fifth cranial nerve as well as the affected nerve to the eye muscle.",
"     </li>",
"     <li>",
"      Pain on eye movement suggests a myopathy or an orbital process. Pain on eye movement but without double vision is also typical of optic neuritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tempo of the problem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the duration of the problem. Sometimes old photographs are useful in doubtful cases. Old photographs are particularly helpful in cases of lid ptosis, fourth nerve palsy, and pupillary abnormalities.",
"   </p>",
"   <p>",
"    Was the onset sudden and has now plateaued, or gradual with steady worsening? Did the pain precede the palsy and resolve shortly after the palsy started? This is a particularly good sign; it is typical of idiopathic or ischemic etiologies (eg, due to diabetes mellitus).",
"   </p>",
"   <p>",
"    Does the motility problem change as the day goes on? This is a typical sign of myasthenia gravis but myasthenia gravis is not necessarily the only cause of this symptom.",
"   </p>",
"   <p>",
"    Finally, one should ask a broad question about any other symptoms, particularly neurologic symptoms, that occurred with the double vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pupil",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the parasympathetic fibers of the third nerve are involved, resulting in pupillary dilation in association with other dysfunction of the third cranial nerve, it is a warning sign of a compressive lesion of the third nerve, typically an aneurysm or, less commonly, a tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31206?source=see_link\">",
"     \"Approach to the patient with anisocoria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other cranial nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second important observation is the possible involvement of any other cranial nerves. Mononeuropathies (dysfunction of only one cranial nerve) are often idiopathic. However, polyneuropathies require a full and extensive neuroradiologic and laboratory workup. Of particular importance are processes that involve the nerves near the third, fourth, and sixth cranial nerves. As examples: the second cranial nerve is concerned with vision, the pupillary light reaction, and visual fields; the fifth cranial nerve is responsible for facial and corneal sensation; abnormalities of the seventh cranial nerve may cause facial droop or weakness of the orbicularis oculi muscle; pathology of the eighth cranial nerve can be suggested by dizziness or loss of hearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H16#H16\">",
"     \"The detailed neurologic examination in adults\", section on 'Cranial nerve examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Globe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important associated observation is the presence or absence of any forward protrusion of the eye, exophthalmos (suggestive of Grave's disease). To assess for the presence of exophthalmos, I like to have the patient look down while I retract the upper lids and I look down past the patient's brow to compare the forward location of the two corneas. A small amount of upper lid ptosis, often present in these cases, will mask the appearance of exophthalmos as viewed from straight ahead. In testing for orbital resiliency, that is how easily can one retroplace the globe digitally, I stand to the side of the patient and observe the eye going back when I press with my finger. This gives me a visual and tactile input.",
"   </p>",
"   <p>",
"    Observe whether the eyeball is congested. Ask the patient to assume the head position that maximizes the double vision and the one that minimizes the double vision. Is there any droopiness of the lid?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ocular motility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Details of the neurologic examination with regard to eye movements are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is often enough merely to observe the eye movement in the right, left, up, and down gaze (",
"    <a class=\"graphic graphic_figure graphicRef58849 \" href=\"UTD.htm?43/36/44609\">",
"     figure 2",
"    </a>",
"    ). In the more profound expressions of ocular motility disturbance, the astute observer can determine which muscle is dysfunctional by making these observations alone. The following are some simple rules:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the double vision is worse on looking to one side and better looking to the other, and if the eyes appear crossed, the problem is most likely that the lateral rectus muscle is not working. Usually this is due to a sixth nerve palsy.",
"     </li>",
"     <li>",
"      If there is some droopiness of the lid and if any combination of the following things is present &mdash; poor inward turning, poor elevation, or poor depression of the eye, then there is probably at least a partial third nerve palsy.",
"     </li>",
"     <li>",
"      If the patient likes to tilt his head to get better vision and if the double vision is primarily vertical and worst looking to one side and down, there is probably a fourth nerve palsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With most patients one can hold a finger vertically or horizontally and move it into different fields of gaze asking in which field of gaze the image separation is the worst and in which it is the best. While you hold the finger in the field of gaze with the worst double vision, cover one eye and ask which image disappears. With a vertical diplopia, when the higher image disappears the eye you covered is lower in position than its partner is and vice-versa. With horizontal diplopia, when the image to the right of the other image disappears, the eye you covered is pointed to the left of its partner. Crossed diplopia means uncrossed eyes and vice-versa.",
"   </p>",
"   <p>",
"    A relatively simple office test that can be helpful is use of a red glass over one eye. This device helps the patient identify the two images more clearly and helps the clinician identify from which eye each image is coming. However, the results of this test should be interpreted with caution; some patients seem to be able to fuse the red and white light with effort. Also, some patients give interpretations which I find confusing, saying for instance, that they see one light on top of the other when they mean that the lights are superimposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Restrictive ophthalmoplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient has a tight and fibrous or entrapped muscle, attempted gaze in the direction away from the field of action of the muscle will result in a rise in intraocular pressure. A rise of 7 mmHg is considered diagnostic of restrictive ophthalmopathy. On examination, the patient will appear to have a weakness of the opponent muscle due to failure of relaxation of the restricted muscle. A patient with Graves' disease will frequently have this problem due to fibrosis of the inferior rectus muscle. In such cases, on attempted upward gaze the intraocular pressure will rise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Quantitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several ways to precisely measure the amount of eye deviation. Prism measurements are commonly used since this number is necessary if the ultimate goal is to correct the deviation with a prism in the glasses, or at least to help the patient with a prism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ETIOLOGY/DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular diplopia may arise due to a number of causes, including a neurogenic lesion (supra-, inter-, or infranuclear), a neuromuscular transmission defect, myopathy, or mechanical restriction in the orbit. An exhaustive summary of these etiologies is the subject of other reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Some helpful clues in patients with vertical or horizontal diplopia and some of the more common acquired causes of diplopia are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vertical diplopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with vertical diplopia complain of seeing two diagonally displaced images, one atop the other. There are many causes of vertical diplopia (",
"    <a class=\"graphic graphic_table graphicRef52647 \" href=\"UTD.htm?42/56/43917\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Vertical diplopia in primary gaze suggests underactivity of the right or left inferior rectus, superior rectus, inferior oblique, or superior oblique [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"     3",
"    </a>",
"    ]. If vertical separation is worse on right gaze, the right superior or inferior rectus or the left inferior or superior oblique may be underactive; separation that is worse looking to the right and down suggests underactivity of the right inferior rectus or left superior oblique. Torsional abnormalities due to oblique muscle involvement should be suspected in patients who complain of image separation that worsens or improves with left or right head tilt.",
"   </p>",
"   <p>",
"    The direction of compensatory head tilt may provide further diagnostic clues. Underaction of the superior or inferior rectus muscles is compensated by chin flexion or extension. Torsional diplopia due to underaction of the oblique muscles may be associated with an angular head tilt.",
"   </p>",
"   <p>",
"    Hypertropia refers to an upward vertical displacement of one eye in primary gaze. A right hypertropia occurs with paresis of the right eye depressors (right inferior rectus or superior oblique) or left eye elevators (left superior rectus or inferior oblique). If the right hypertropia increases in left gaze, either the right superior oblique or the left superior rectus muscle is underacting. If the vertical deviation increases with right head tilt, the right superior oblique muscle is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A skew eye deviation presenting with hypertropia and vertical diplopia can result from an imbalance in the vestibular system. In such patients, the diplopia typically does not match ocular muscle function and the deviation changes when the patient is tested sitting versus lying down. These features can distinguish a skew eye deviation from extraocular paresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Horizontal diplopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horizontal diplopia is usually due to disease processes that affect the medial or lateral rectus muscles or the innervation of these muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/2\">",
"     2",
"    </a>",
"    ]. The images appear side by side; as mentioned above, image separation that is worse at a distance is typical of a sixth nerve palsy, while image separation that is worse at near is typical of a medial rectus palsy. An esotropia refers to a medial deviation of the eye at primary gaze, an exotropia refers to lateral deviation in primary gaze. There are many causes of horizontal diplopia (",
"    <a class=\"graphic graphic_table graphicRef56887 \" href=\"UTD.htm?43/15/44285\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fourth cranial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial nerve IV palsy is a common cause of vertical diplopia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"     3",
"    </a>",
"    ]. Most fourth nerve palsies are either traumatic or idiopathic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with congenital fourth nerve palsy are often able to compensate for the double vision with a head tilt that minimizes symptoms. Over time, however, they may have increasing difficulty controlling the symptoms and present with diplopia. The patient may insist that this is a new problem, although old photos frequently demonstrate a head tilt [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/4\">",
"     4",
"    </a>",
"    ]. A peculiar feature of congenital fourth nerve palsy is that the amount of hypertropia in the primary position is very large (deviations as high as 20 or 30 prism diopters). A true acquired fourth nerve palsy of recent onset will have a hypertropia that measures prism diopters in the mid-teens in the primary position at the most [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Traumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic fourth nerve palsies, in contrast to traumatic third and sixth nerve palsies, may occur with a relatively mild blow to the head that is not associated with loss of consciousness or a skull fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/6\">",
"     6",
"    </a>",
"    ]. Some traumatic fourth nerve palsies improve with time, but most do not. Careful examination is important to exclude bilateral fourth nerve palsies which can be very asymmetrical; it is unfortunate for a surgeon to have corrected a fourth nerve palsy by weakening the ipsilateral inferior oblique muscle, only to find a contralateral fourth nerve palsy now uncovered and obvious to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic fourth nerve palsies, like idiopathic third and sixth nerve palsies, often present with pain over the eyebrow of the affected eye that stops shortly after the diplopia starts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. When asked to point to the pain, patients usually indicate an area just above the brow on the side of the muscle weakness. Rarely does the pain require medication. The best time to diagnose a third, fourth, or sixth nerve palsy is early in its course. If the palsy does not resolve there is a tendency for the deviation to become more \"comitant.\" This means the hypertropia, esotropia, or exotropia that was once limited largely to one field of gaze will creep into the opposite field due to the contraction and thus overaction of the antagonistic muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely a fourth nerve palsy can be due to raised intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/14\">",
"     14",
"    </a>",
"    ]. It is important to look carefully at the optic nerve head to be sure that there is no papilledema.",
"   </p>",
"   <p>",
"    The fourth nerve exits from the dorsum of the brainstem. Thus, neurologic signs of cerebellar disease may be present if a tumor in that region is causing the fourth nerve palsy.",
"   </p>",
"   <p>",
"    Most fourth cranial nerve palsies are either idiopathic or traumatic. The idiopathic ones usually resolve in a few weeks. I typically postpone neuroradiologic testing until two months have passed without improvement as long as the other cranial nerves are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Third cranial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third cranial nerve palsies may cause both vertical and horizontal diplopia. Patients with a complete unilateral third nerve palsy have ptosis, a large unreactive pupil, and paralysis of adduction, elevation, and depression; the eye rests in a position of abduction, slight depression, and intorsion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"     3",
"    </a>",
"    ]. The asymmetry of pupil size is greater in the light than in the dark.",
"   </p>",
"   <p>",
"    Absence of pupillary involvement suggests a benign process that can be observed over a couple of weeks. A fixed, dilated pupil requires extensive neurologic evaluation. Partial involvement of the pupil (defined in one report as anisocoria greater than 0.5 but less than 2.0 mm in room light, and whose affected pupil maintained reactivity to light) may be associated with either serious or benign underlying pathologies; neuroimaging is indicated in these individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sixth nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sixth cranial nerve palsies primarily complain of horizontal diplopia, although they may also complain of slight vertical diplopia. On examination there is an esotropia (inward deviation) that is worsened with gaze into the field of the weak lateral rectus muscle. To limit diplopia, patients may assume a compensatory face turn in the direction of the paralyzed muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/2\">",
"     2",
"    </a>",
"    ]. Abduction is commonly limited on the side of the lesion.",
"   </p>",
"   <p>",
"    Patients with idiopathic sixth nerve palsy often present with the sudden onset of horizontal diplopia that is better at near and worse at a distance. There may be minor pain over the affected eyebrow at the onset of the double vision, but no disturbing pain distributed over the forehead or face. The remainder of the neurologic examination is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/18\">",
"     18",
"    </a>",
"    ]. Poorly controlled diabetes is a predisposing factor, and one population-based study found that patients with isolated six nerve palsy had a six-fold increase in the odds of diabetes compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/19\">",
"     19",
"    </a>",
"    ]. Other causes of sixth nerve palsy are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef80526 \" href=\"UTD.htm?42/39/43645\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A sudden onset distinguishes idiopathic sixth cranial nerve palsies from tumor or myasthenia gravis. Spontaneous improvement over several weeks to months is expected, and failure to improve suggests more serious intracranial pathology. As an example, in a study of 213 patients with unilateral isolated sixth nerve palsies in whom trauma was excluded, 78 percent experienced spontaneous recovery of their palsy, 37 percent recovering by 8 weeks and 74 percent by 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/20\">",
"     20",
"    </a>",
"    ]. Only 16 percent failed to recover; of this group, however, almost 40 percent had serious underlying pathology accounting for their palsy.",
"   </p>",
"   <p>",
"    Patients with bilateral sixth nerve palsy will have progressive horizontal double vision as a presenting symptom. The point of least inward turn will always be to the side of the stronger lateral rectus. One may have to depend upon observation of the abducting eye to decide if both lateral recti are weak. This decision is very important. An ominous sign in any cranial nerve palsy is the involvement of any other cranial nerve, even its partner on the other side [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/21\">",
"     21",
"    </a>",
"    ]. The sixth nerve is a case in point because it has a long and relatively isolated course after it exits the brainstem, climbs up the clivus, and passes through the cavernous sinus. This allows certain tumors to affect both sixth nerves before any other parts of the brain are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other nerves to pay particular attention to when dealing with sixth nerve palsies are the fifth nerve, pointing to a lesion in the cavernous sinus, and papilledema, suggesting a mass lesion causing raised intracranial pressure and displacement of the brainstem and thus stretching of one or both sixth nerves. Involvement of cranial nerve V causes reduced facial sensation, often around the upper face and cornea. Despite the anesthesia in this area, however, patients with mass lesions may complain of severe pain around the eye (often requiring opiates).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Internuclear ophthalmoplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internuclear ophthalmoplegia is a specific gaze abnormality characterized by impaired horizontal eye movement with weak adduction of the affected eye and abduction nystagmus of the contralateral eye. This results from a lesion (usually stroke or demyelination) in the medial longitudinal fasciculus in the dorsomedial brainstem tegmentum of either the pons or the midbrain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20246?source=see_link\">",
"     \"Internuclear ophthalmoplegia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extraocular eye muscles are often involved in myasthenia gravis (MG). The clinical manifestations vary from subtle blurring of vision to severe diplopia. MG-induced diplopia can mimic an internuclear ophthalmoplegia. Weakness of the eye muscles in MG can also produce ptosis, the degree of which is variable, switching from one eye to the other on separate examinations and occasionally increasing with sudden exposure to bright light. Most patients with MG do not complain of eye pain or headache. Fatigability and variability of clinical findings are characteristic.",
"   </p>",
"   <p>",
"    Physical examination may reveal unusual eye movements that do not conform to the anatomy of one nerve or muscle. The pupils are always spared in MG, helping in the differentiation from other disorders such as botulism. The diagnosis and treatment of myasthenia gravis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"     \"Ocular myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Thyroid ophthalmopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ophthalmopathy is a common cause of horizontal or vertical diplopia. Restriction of extraocular movement preferentially affects the inferior rectus, medial rectus, and superior rectus, in that order [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"     3",
"    </a>",
"    ]. Because the process causes muscle tightness or restriction, the diplopia is worse in the direction opposite that of the involved muscle action [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, hypertropia (upward vertical deviation) and esotropia (medial deviation) are common in patients with thyroid ophthalmopathy, but exotropia (lateral deviation) is uncommon because the lateral rectus muscle is usually not involved.",
"   </p>",
"   <p>",
"    Limitation in elevation of one or both eyes with vertical misalignment is the most common defect of ocular motility in these individuals. The other characteristic signs of thyroid ophthalmopathy include proptosis and periorbital edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ophthalmoplegic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmoplegic migraine is rare and most often seen in children and young adults. It is a diagnosis that should be made only after other disorders have been ruled out. It may affect the third (most common), fourth, or sixth cranial nerves. Extraocular muscle paralysis can occur with the first attack of headache or, rarely, precede it. Permanent damage to the third nerve has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/25\">",
"     25",
"    </a>",
"    ]. Other causes of painful ophthalmoplegia (eg, aneurysm) should be excluded with neuroimaging studies.",
"   </p>",
"   <p>",
"    Ophthalmoplegic migraine is now considered a cranial neuralgia because MRI gadolinium enhancement of the cisternal segment of the affected cranial nerve has been demonstrated in patients with a typical clinical presentation, suggesting that the condition may be a recurrent demyelinating neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H13436656#H13436656\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Ophthalmoplegic migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Wernicke's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wernicke's syndrome is caused by thiamine deficiency and is typically associated with alcohol abuse. Patients with Wernicke's encephalopathy may complain of vertical diplopia due to a supranuclear or nuclear lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Orbital myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orbital myositis is an idiopathic inflammation of an extraocular muscle. The diagnosis should be considered in patients who have seemingly isolated extraocular muscle dysfunction, especially in the distribution of cranial nerve III.",
"   </p>",
"   <p>",
"    Patients present with acute or subacute orbital pain and horizontal diplopia; absence of pain suggests an alternate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. On physical examination there may be conjunctival chemosis and injection, ptosis, and proptosis. The process can be unilateral or bilateral. Neuroimaging reveals a focal or diffuse inflammatory lesion. The disorder usually resolves with corticosteroids&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/28\">",
"     28",
"    </a>",
"    ], particularly in severe cases, although in my experience corticosteroids tend to prolong the course of what might otherwise be a self-limited illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Tolosa-Hunt syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tolosa-Hunt syndrome is a rare syndrome, which is characterized by painful ophthalmoplegia and is caused by an idiopathic granulomatous inflammation of the cavernous sinus. This syndrome responds to corticosteroid therapy.",
"   </p>",
"   <p>",
"    While considered a benign condition, permanent neurologic deficits can occur, and relapses are common, often requiring prolonged immunosuppressive therapy. Tolosa-Hunt syndrome must also be carefully differentiated from more commonly occurring malignancies and infections involving the cavernous sinus, a task made difficult by the lack of a specific diagnostic test abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24006?source=see_link\">",
"     \"Tolosa-Hunt syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other pathologies can lead to diplopia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ophthalmoplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25320/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute inflammatory demyelinating polyneuropathy (Guillain-Barr&eacute; syndrome) can affect the extraocular muscle function as a presenting manifestation. This is often referred to as the Fisher or Miller Fisher variant. Typically, deep tendon reflexes are also absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link&amp;anchor=H389462#H389462\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\", section on 'Miller Fisher syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tick bite paralysis and botulism are neuromuscular junction pathologies that can lead to extraocular muscle weakness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"       \"Botulism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3494?source=see_link\">",
"       \"Tick paralysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Structural lesions (metastases, infections) affecting the skull base cavernous sinus can lead to a cranial polyneuropathy with diplopia as the primary manifestation.",
"     </li>",
"     <li>",
"      Giant cell arteritis can present with diplopia, usually with other suggestive clinical features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to establish a standard guideline for the evaluation of diplopia. Multiple possible etiologies exist, many of which can be serious. Some important caveats are helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first rule is to determine if a single nerve is involved. Involvement of other nerves, even the opposite cranial nerve (eg, bilateral sixth nerve palsy), suggests a more serious underlying disorder and requires more extensive evaluation, including neuroimaging (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24006?source=see_link&amp;anchor=H4#H4\">",
"       \"Tolosa-Hunt syndrome\", section on 'Differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24006?source=see_link&amp;anchor=H5#H5\">",
"       \"Tolosa-Hunt syndrome\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The second question is whether there is a medical excuse for the problem. As an example, one is more likely to work up a young person with a sixth nerve palsy than an older person in his seventies.",
"     </li>",
"     <li>",
"      Signs of improvement over time almost always means the process is benign. Isolated fourth or sixth never palsies can be observed for a few weeks. More extensive work-up should be done if the palsy does not resolve or if other symptoms appear.",
"     </li>",
"     <li>",
"      The presence of severe headache of sudden onset demands an urgent evaluation for cerebral aneurysm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62881940\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binocular diplopia (double vision with both eyes open and absent when either eye is closed) often results from dysfunction of one or more of the extraocular muscles. In contrast monocular diplopia, which persists when one eye is closed, suggests local eye disease or a refractive problem. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Presentation/history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three pairs of extraocular muscles move each eye in three directions: vertically (superior and inferior), horizontally (medial and lateral), and torsionally (intorsion when the eye rotates toward the patient's nose and extorsion when the eye rotates toward the patient's shoulder) (",
"      <a class=\"graphic graphic_table graphicRef72952 \" href=\"UTD.htm?37/58/38827\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75770 \" href=\"UTD.htm?1/37/1620\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58849 \" href=\"UTD.htm?43/36/44609\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neuroanatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence or absence of pain is an important distinguishing feature in considering a differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef77825 \" href=\"UTD.htm?3/54/3949\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Presentation/history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The examination should focus on establishing which particular extraocular muscle or muscles may be weak. The presence of pupillary or other cranial nerve abnormality and other ocular findings are also important. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the pattern of muscle weakness suggests that the problem is isolated to a single cranial nerve, the differential diagnosis is specific to the individual nerve:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For third nerve palsies, the presence or absence of pupillary involvement and other associated signs is critical to localization and diagnosis (",
"      <a class=\"graphic graphic_table graphicRef56375 \" href=\"UTD.htm?30/4/30796\">",
"       table 6",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=see_link\">",
"       \"Third cranial nerve (oculomotor nerve) palsy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"       \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most fourth cranial nerve palsies are idiopathic or traumatic in etiology. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Fourth cranial nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sixth nerve palsies cause isolated weakness of abduction, and may result from poorly controlled diabetes, among other causes (",
"      <a class=\"graphic graphic_table graphicRef80526 \" href=\"UTD.htm?42/39/43645\">",
"       table 5",
"      </a>",
"      ). Bilateral sixth nerve palsies may be seen in elevated intracranial pressure. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Sixth nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Internuclear ophthalmoplegia is a specific gaze abnormality characterized by impaired horizontal eye movement with weak adduction of the affected eye and abduction nystagmus of the contralateral eye. This results from a lesion (usually stroke or demyelination) in the medial longitudinal fasciculus in the dorsomedial brainstem tegmentum of either the pons or the midbrain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20246?source=see_link\">",
"       \"Internuclear ophthalmoplegia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The extraocular eye muscles are often involved in myasthenia gravis (MG). Multiple extraocular muscles in both eyes are typically involved and ptosis is also often present. Fatigability and variability of clinical findings are characteristic clues to this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"       \"Ocular myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid ophthalmopathy leads to muscle tightness and restriction of movement. Proptosis is usually also present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"       \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes of binocular diplopia affecting multiple, bilateral extraocular muscles include: orbital myositis, Tolosa-Hunt syndrome, Miller Fisher variant of acute inflammatory demyelinating polyneuropathy, and structural",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inflammatory lesions involving the skull base cavernous sinus, or basilar meninges. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Etiology/diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/1\">",
"      Keane JR. Triplopia: thirteen patients from a neurology inpatient service. Arch Neurol 2006; 63:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/2\">",
"      Brazis PW, Lee AG. Acquired binocular horizontal diplopia. Mayo Clin Proc 1999; 74:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/3\">",
"      Brazis PW, Lee AG. Binocular vertical diplopia. Mayo Clin Proc 1998; 73:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/4\">",
"      Brazis PW. Palsies of the trochlear nerve: diagnosis and localization--recent concepts. Mayo Clin Proc 1993; 68:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/5\">",
"      Mittelman D, Folk ER. The evaluation and treatment of superior oblique muscle palsy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1976; 81:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/6\">",
"      Sydnor CF, Seaber JH, Buckley EG. Traumatic superior oblique palsies. Ophthalmology 1982; 89:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/7\">",
"      Helveston EM, Mora JS, Lipsky SN, et al. Surgical treatment of superior oblique palsy. Trans Am Ophthalmol Soc 1996; 94:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/8\">",
"      Kushner BJ. The diagnosis and treatment of bilateral masked superior oblique palsy. Am J Ophthalmol 1988; 105:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/9\">",
"      Lee J, Flynn JT. Bilateral superior oblique palsies. Br J Ophthalmol 1985; 69:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/10\">",
"      Coppeto JM, Lessell S. Cryptogenic unilateral paralysis of the superior oblique muscle. Arch Ophthalmol 1978; 96:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/11\">",
"      von Noorden GK, Murray E, Wong SY. Superior oblique paralysis. A review of 270 cases. Arch Ophthalmol 1986; 104:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/12\">",
"      Beard CM, Benson RC Jr, Kelalis PP, Elveback LR. Incidence of malignant testicular tumors in the population of Rochester, Minnesota, 1935 through 1974. Mayo Clin Proc 1977; 52:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/13\">",
"      Ellis FD, Helveston EM. Superior oblique palsy: diagnosis and classification. Int Ophthalmol Clin 1976; 16:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/14\">",
"      Halpern JI, Gordon WH Jr. Trochlear nerve palsy as a false localizing sign. Ann Ophthalmol 1981; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/15\">",
"      Bagolini B, Campos EC, Chiesi C. Plagiocephaly causing superior oblique deficiency and ocular torticollis. A new clinical entity. Arch Ophthalmol 1982; 100:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/16\">",
"      Keane JR. Fourth nerve palsy: historical review and study of 215 inpatients. Neurology 1993; 43:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/17\">",
"      Jacobson DM. Relative pupil-sparing third nerve palsy: etiology and clinical variables predictive of a mass. Neurology 2001; 56:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/18\">",
"      Bixenman WW, von Noorden GK. Benign recurrent VI nerve palsy in childhood. J Pediatr Ophthalmol Strabismus 1981; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/19\">",
"      Patel SV, Holmes JM, Hodge DO, Burke JP. Diabetes and hypertension in isolated sixth nerve palsy: a population-based study. Ophthalmology 2005; 112:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/20\">",
"      King AJ, Stacey E, Stephenson G, Trimble RB. Spontaneous recovery rates for unilateral sixth nerve palsies. Eye (Lond) 1995; 9 ( Pt 4):476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/21\">",
"      Gutman I, Levartovski S, Goldhammer Y, et al. Sixth nerve palsy and unilateral Horner's syndrome. Ophthalmology 1986; 93:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/22\">",
"      Insel TR, Kalin NH, Risch SC, et al. Abducens palsy after lumbar puncture. N Engl J Med 1980; 303:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/23\">",
"      Kline LB, Glaser JS. Bilateral abducens nerve palsies from clivus chordoma. Ann Ophthalmol 1981; 13:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/24\">",
"      Neuberger J, Bone I. Bilateral sixth cranial nerve palsy in infectious mononucleosis. Postgrad Med J 1979; 55:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/25\">",
"      Bartleson JD. Transient and persistent neurological manifestations of migraine. Stroke 1984; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/26\">",
"      Slavin ML, Glaser JS. Idiopathic orbital myositis: report of six cases. Arch Ophthalmol 1982; 100:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/27\">",
"      Smith JL, Taxdal DS. Painful ophthalmoplegia. The Tolosa-Hunt syndrome. Am J Ophthalmol 1966; 61:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/28\">",
"      Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology 1997; 104:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25320/abstract/29\">",
"      Keane JR. Bilateral ocular paralysis: analysis of 31 inpatients. Arch Neurol 2007; 64:178.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5238 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25320=[""].join("\n");
var outline_f24_46_25320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H62881940\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRESENTATION/HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diplopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tempo of the problem",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other cranial nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Globe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ocular motility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Restrictive ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ETIOLOGY/DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vertical diplopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Horizontal diplopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fourth cranial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Congenital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Traumatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Third cranial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sixth nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Thyroid ophthalmopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ophthalmoplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Wernicke's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Orbital myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Tolosa-Hunt syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62881940\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5238|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/37/1620\" title=\"figure 1\">",
"      Eye muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/36/44609\" title=\"figure 2\">",
"      Positions of gaze",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/58/38827\" title=\"table 1\">",
"      Actions extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/54/3949\" title=\"table 2\">",
"      Causes of painful ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/56/43917\" title=\"table 3\">",
"      Causes of vertical diplopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/15/44285\" title=\"table 4\">",
"      Causes of horizontal diplopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/39/43645\" title=\"table 5\">",
"      Causes of sixth nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/4/30796\" title=\"table 6\">",
"      Causes of third nerve palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31206?source=related_link\">",
"      Approach to the patient with anisocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20246?source=related_link\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3494?source=related_link\">",
"      Tick paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24006?source=related_link\">",
"      Tolosa-Hunt syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_46_25321="Jones metroplasty AB";
var content_f24_46_25321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Jones metroplasty AB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 628px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) In the Jones procedure, the common cavity is initially reached through a wedge resection of the septum. (B) The septum is totally removed as the two cavities are unroofed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25321=[""].join("\n");
var outline_f24_46_25321=null;
var title_f24_46_25322="Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma";
var content_f24_46_25322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/46/25322/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/46/25322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular lymphoma (FL, previously called follicle center lymphoma) is a heterogeneous clinicopathologic entity that includes tumors derived from germinal center B cells, both centrocytes (small cleaved follicular center cells) and centroblasts (large noncleaved follicular center cells), and virtually always demonstrates a growth pattern that is partially follicular. FL is the second most common subtype of non-Hodgkin lymphoma (NHL). It is the most common of the clinically indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, pathologic features, diagnosis, and prognosis of FL will be reviewed here. The pathobiology and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"     \"Pathobiology of follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL is one of the most common forms of non-Hodgkin lymphoma. The exact worldwide incidence of FL is not known, as collection of these types of epidemiologic data is limited in some countries by a lack of resources that are needed for case ascertainment and accurate diagnosis. While FL occurs in all races and all geographic locations, epidemiologic data largely come from retrospective analyses of patients treated at major centers in the United States and Europe.",
"   </p>",
"   <p>",
"    In the United States as a whole, FL accounts for approximately 35 percent of NHLs and has an estimated incidence of 3.18 cases per 100,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/1\">",
"     1",
"    </a>",
"    ]. The estimated incidence in Europe is 2.18 cases per 100,000 persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence is stable over time, but varies by ethnicity with the incidence in Whites being more than twice that in Black and Asian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. FL appears to be less common in Central and South America, where it accounts for approximately 20 percent of NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/4\">",
"     4",
"    </a>",
"    ]. There is no strong sex predilection. The incidence increases with age; FL most frequently presents in middle-aged individuals and the elderly, with a median age at diagnosis of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/5\">",
"     5",
"    </a>",
"    ]. Rarely, FL arises in children or adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Children'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While numerous potential risk factors have been proposed, most have not been validated in independent studies. As such, there is a lack of consensus regarding risk factors for the development of FL. A small number of cases appear to be familial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. While the risk of developing FL is slightly increased among relatives of persons with FL, the absolute risk remains low [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/12\">",
"     12",
"    </a>",
"    ]. Diseases, infectious agents, and drugs or toxins associated with the development of NHL in general are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Past history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL is thought to arise from germinal center B cells, both centrocytes (small cleaved follicular center cells) and centroblasts (large noncleaved follicular center cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of follicular lymphoma is incompletely understood. Approximately 85 percent of patients with FL have t(14;18), which results in the overexpression of B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (",
"    <em>",
"     BCL2",
"    </em>",
"    ), an oncogene that blocks programmed cell death (apoptosis), leading to prolonged cell survival. However, it is clear that multiple genetic events are required for the development of FL since the t(14;18) translocation can be identified in normal individuals and patients with diffuse large B cell lymphoma. The pathogenesis of FL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243868#H26243868\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"     \"Pathobiology of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with FL present with painless peripheral adenopathy in the cervical, axillary, inguinal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    femoral regions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/5,15,16\">",
"     5,15,16",
"    </a>",
"    ]. The adenopathy commonly waxes and wanes spontaneously, but does not altogether disappear. While hilar and mediastinal nodes are often involved, large mediastinal masses are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/17\">",
"     17",
"    </a>",
"    ]. Some patients present with relatively asymptomatic large abdominal masses with or without evidence of gastrointestinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urinary tract obstruction. Staging studies usually demonstrate widely disseminated disease with overt involvement of the spleen, liver,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow in approximately 40, 50, and 60 to 80 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the presence of widespread disease at diagnosis, most patients are asymptomatic other than for lymph node enlargement. Only approximately 20 percent presents with B symptoms (ie, fevers, night sweats, or unintentional weight loss) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/17\">",
"     17",
"    </a>",
"    ]. There are no characteristic laboratory abnormalities specifically associated with FL and, despite the large tumor burden, fewer than 25 percent of patients present with an increased serum lactate dehydrogenase (LDH) or cytopenias in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/17\">",
"     17",
"    </a>",
"    ]. Staging of lymphoma and the definitions of systemic symptoms associated with lymphoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Systemic complaints (B symptoms)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of organs other than the lymphatic organs or bone marrow is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/19\">",
"     19",
"    </a>",
"    ]. Central nervous system involvement is rare, but peripheral nerve compression and epidural tumor masses causing cord compression may develop. Other patients have disease localized to the small intestine, most commonly the second portion of the duodenum, frequently identified as an incidental finding during endoscopy performed for other reasons. The morphology, immunophenotype, and genetic features of such \"primary intestinal follicular lymphomas\" are similar to those of nodal FL. The clinical presentation of gastrointestinal lymphoma in general is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H99000111\">",
"     'Primary intestinal follicular lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, FL arises in children or adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/6-9,20\">",
"     6-9,20",
"    </a>",
"    ]. A substantial proportion of these pediatric FL tumors appear to be biologically distinct from typical adult FL.",
"   </p>",
"   <p>",
"    Characteristics of childhood FL include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low stage disease (generally stage",
"      <span class=\"nowrap\">",
"       I/II)",
"      </span>",
"     </li>",
"     <li>",
"      Frequent involvement of the head and neck region",
"     </li>",
"     <li>",
"      Predominance of grade III histology",
"     </li>",
"     <li>",
"      Infrequent presence of BCL-2 protein expression (approximately 30 percent) or of",
"      <em>",
"       BCL2",
"      </em>",
"      rearrangements (approximately 10 percent)",
"     </li>",
"     <li>",
"      A high rate of apparent cure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, adults may present with localized tumors that pathologically resemble childhood FL (BCL2 negative with a high proliferation index) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/20\">",
"     20",
"    </a>",
"    ]. Such cases appear to have a high rate of cure following localized therapy. Conversely, childhood tumors with",
"    <em>",
"     BCL2",
"    </em>",
"    rearrangements appear to be more likely to pursue a course like typical adult FL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/9,20\">",
"     9,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Morphologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;On histology, the growth pattern and cell morphology can help to identify FL. Enumeration of centroblasts is used to determine the tumor grade, which has therapeutic implications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Growth pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most notable morphologic features of FL is its nodular growth pattern (",
"    <a class=\"graphic graphic_picture graphicRef85888 \" href=\"UTD.htm?8/12/8394\">",
"     picture 1",
"    </a>",
"    ), which recapitulates the normal germinal centers of secondary lymphoid follicles (",
"    <a class=\"graphic graphic_picture graphicRef69885 \" href=\"UTD.htm?20/20/20805\">",
"     picture 2",
"    </a>",
"    ) and effaces the normal lymphoid architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15\">",
"     15",
"    </a>",
"    ]. Unlike normal lymph nodes, the nodules in FL are typically closely packed and vary in size and shape. There is often artifactual cracking around the nodules in tissue sections, presumably because the follicles lack the normal stromal elements that surround and support reactive follicles. When necessary, staining for follicular dendritic cells (eg, CD21, CD23) can aid in the identification of follicles by increasing their prominence.",
"   </p>",
"   <p>",
"    The neoplastic follicles may be present throughout the tumor tissue, or only a portion, with a diffuse component occupying the rest of the tumor (",
"    <a class=\"graphic graphic_picture graphicRef79473 \" href=\"UTD.htm?30/34/31268\">",
"     picture 3",
"    </a>",
"    ). Similar to normal germinal centers, T cells and tightly organized meshworks of follicular dendritic cells are present within the malignant follicles; however, unlike in normal follicles, so-called tingible body macrophages (cells laden with the remnants of B cells that have died by apoptosis) are typically absent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interfollicular areas of FLs, although compressed, also resemble normal lymph nodes in that large numbers of normal T cells are often located there, mixed with variable numbers of neoplastic cells. The Ki-67+ fraction, a marker of proliferation, is generally lower in neoplastic follicles than it is in reactive follicles. The number of Ki-67+ cells and mitotic figures increases with grade (",
"    <a class=\"graphic graphic_picture graphicRef85889 \" href=\"UTD.htm?20/56/21386\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85887 \" href=\"UTD.htm?15/49/16154\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rarely, biopsy of involved tissue demonstrates a diffuse infiltration of tumor cells without a nodular growth pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15\">",
"     15",
"    </a>",
"    ]. Most of these cases are thought to represent a sampling error in which a small biopsy misses areas of nodular growth. A diagnosis of FL may be made in these cases if other criteria for the diagnosis are present, including a classic immunophenotype (ie, germinal center cell phenotype) and genetic features (ie, 14;18 translocation) associated with FL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cell morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor is composed of follicle center cells, usually a mixture of centrocytes and centroblasts (",
"    <a class=\"graphic graphic_picture graphicRef63064 \" href=\"UTD.htm?34/49/35606\">",
"     picture 8B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Centrocytes (cleaved follicle center cells) are small to medium sized cells with elongated or cleaved nuclei, inconspicuous nucleoli and scant pale cytoplasm (",
"      <a class=\"graphic graphic_picture graphicRef74837 \" href=\"UTD.htm?25/56/26502\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Centroblasts (noncleaved follicle center cells) are large cells with round or oval nuclei, vesicular chromatin, often multiple peripheral nucleoli and a narrow rim of basophilic cytoplasm (",
"      <a class=\"graphic graphic_picture graphicRef74413 \" href=\"UTD.htm?12/12/12487\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Centrocytes typically predominate in FL; centroblasts are usually in the minority, but by definition are always present. Rare lymphomas with a follicular growth pattern consist almost entirely of centroblasts (grade III FL). Occasional cases may show plasmacytoid differentiation or foci of marginal zone or monocytoid B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of centroblasts (large cells) varies from case to case, and the clinical aggressiveness of the tumor increases with increasing numbers of centroblasts. Numerous criteria have been proposed for grading FL. The WHO Classification has adopted the following cell-counting method [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15,25-28\">",
"     15,25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &mdash; 0 to 5",
"      <span class=\"nowrap\">",
"       centroblasts/high",
"      </span>",
"      power field (hpf) (follicular small cleaved) (",
"      <a class=\"graphic graphic_picture graphicRef74837 \" href=\"UTD.htm?25/56/26502\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade II &mdash; 6 to 15",
"      <span class=\"nowrap\">",
"       centroblasts/hpf",
"      </span>",
"      (follicular mixed) (",
"      <a class=\"graphic graphic_picture graphicRef85890 graphicRef63064 \" href=\"UTD.htm?38/55/39802\">",
"       picture 8A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade III &mdash; More than 15",
"      <span class=\"nowrap\">",
"       centroblasts/hpf",
"      </span>",
"      (follicular large cell) (",
"      <a class=\"graphic graphic_picture graphicRef74413 \" href=\"UTD.htm?12/12/12487\">",
"       picture 7",
"      </a>",
"      ). Grade III has been subdivided for investigational purposes into grade IIIa, in which centrocytes are present, and grade IIIb, in which there are solid sheets of centroblasts [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic value of FL grade is discussed below. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Tumor grade'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Blood and bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow involvement is common and mainly takes the form of paratrabecular lymphoid aggregates (",
"    <a class=\"graphic graphic_picture graphicRef85886 \" href=\"UTD.htm?29/28/30153\">",
"     picture 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/30\">",
"     30",
"    </a>",
"    ]. Low-level involvement of the peripheral blood is often detected by flow cytometry, but overt involvement of the blood (eg, sufficient to be appreciated on the peripheral smears) is unusual. Morphologically, these circulating cells have notches or clefts, and correspond to centrocytes (",
"    <a class=\"graphic graphic_picture graphicRef65023 \" href=\"UTD.htm?23/54/24416\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of FL is usually confirmed by immunohistochemistry (",
"    <a class=\"graphic graphic_picture graphicRef85885 \" href=\"UTD.htm?24/63/25594\">",
"     picture 11",
"    </a>",
"    ), but may also be demonstrated using flow cytometry (",
"    <a class=\"graphic graphic_figure graphicRef85884 \" href=\"UTD.htm?23/55/24437\">",
"     figure 1",
"    </a>",
"    ). FL is a B cell malignancy thought to arise from germinal center cells. The key features are the presence of B cell markers and lack of T cell markers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tumor cells usually demonstrate surface immunoglobulin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/31\">",
"       31",
"      </a>",
"      ]; approximately 50 to 60 percent express IgM, 40 percent express IgG, and rare cases express IgA. Either kappa or lambda light chains should be present, but not both.",
"     </li>",
"     <li>",
"      Virtually all cases express HLA-DR; are positive for certain pan B cell antigens (CD19, CD20, CD79a), CD21, and CD10 (60 percent); and lack expression of CD5, CD43 (most cases), and CD11c. CD23 expression is variable [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytoplasmic staining for BCL-2 protein is strongly positive in almost all grade",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      tumors, which is in contrast to hyperplastic normal germinal center B cells, which are BCL-2 negative (",
"      <a class=\"graphic graphic_picture graphicRef64808 \" href=\"UTD.htm?37/54/38761\">",
"       picture 12",
"      </a>",
"      ). However, a high fraction of cutaneous FL, childhood FL, and systemic grade III FLs is BCL-2 negative. The transcription factor B cell lymphoma 6 (BCL-6) is expressed by at least some of the neoplastic cells in all FL tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular genetics can help confirm the presence of clonal immunoglobulin gene rearrangements and an",
"    <span class=\"nowrap\">",
"     IgH/BCL2",
"    </span>",
"    fusion gene, which is the product of the t(14;18). &ldquo;Deep&rdquo; sequencing of FL genomes has revealed that most tumors (89 percent) have mutations in",
"    <em>",
"     MLL2",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/36\">",
"     36",
"    </a>",
"    ], a gene encoding a histone methyltransferase that stimulates RNA elongation; the functional and clinical significance of",
"    <em>",
"     MLL2",
"    </em>",
"    mutations remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Immunoglobulin genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin heavy and light chain genes are rearranged, and analysis of the immunoglobulin variable region genes shows that most cases have extensive somatic mutations and a high frequency of intraclonal diversity, indicating ongoing mutations, similar to normal germinal center cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cytogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FL frequently have chromosomal abnormalities, but there is no single chromosomal change that is diagnostic of this disease. In the vast majority of cases, FL is associated with a translocation between the long arm of chromosome 18, the site of the",
"    <em>",
"     BCL2",
"    </em>",
"    oncogene (18q21), and one of three immunoglobulin (Ig) gene loci [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Ig heavy chain gene on chromosome 14 &mdash; resulting in the t(14;18)(q32;q21) found in approximately 85 percent of FL",
"     </li>",
"     <li>",
"      The kappa light chain gene on chromosome 2 &mdash; resulting in the t(2;18)(p11;q21), which is uncommon but considered a biologic equivalent",
"     </li>",
"     <li>",
"      The lambda light chain gene on chromosome 22 &mdash; resulting in the t(18;22)(q21;q21), which is uncommon but considered a biologic equivalent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The consequence of these translocations is the presence within the cells of constitutively high levels of BCL-2 protein, resulting in resistance to apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. The t(14;18) translocation is not specific for FL, as it is also found in up to 30 percent of diffuse large B cell lymphomas and in a small number of reactive germinal center B cells in many lymph nodes undergoing follicular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/42,44-48\">",
"     42,44-48",
"    </a>",
"    ]. The pathogenesis of FL and the role of BCL-2 in the development of FL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243868#H26243868\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"     \"Pathobiology of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 5 to 15 percent of FL tumors have 3q27 abnormalities, involving the",
"    <em>",
"     BCL6",
"    </em>",
"    gene, which encodes a transcription factor that is essential for normal germinal center development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/29,49\">",
"     29,49",
"    </a>",
"    ]. The incidence of",
"    <em>",
"     BCL6",
"    </em>",
"    rearrangements increases with histologic grade, being most common in tumors with grade IIIb histology, and appears to be associated with a more aggressive clinical course. Although some series have suggested that",
"    <em>",
"     BCL6",
"    </em>",
"    rearrangements and",
"    <em>",
"     BCL2",
"    </em>",
"    rearrangements are mutually exclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/29\">",
"     29",
"    </a>",
"    ], more recent studies have identified tumors with both rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <em>",
"     BCL6",
"    </em>",
"    gene rearrangements associated with abnormalities of chromosome 3q27 are also seen in a subset of diffuse large B cell lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of FL is best made by excisional tissue biopsy, most commonly a lymph node. The histologic examination is essential, while immunophenotypic and molecular genetic studies can help to support a suspected diagnosis. A discussion of lymph node and tissue biopsy, including the selection of a lymph node to biopsy, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Lymph node and tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients will have systemic follicular lymphoma. The 2008 WHO classification of tumors of hematopoietic and lymphoid tissues recognizes three additional clinical variants of FL:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pediatric follicular lymphoma &mdash; (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Children'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Intrafollicular",
"      <span class=\"nowrap\">",
"       neoplasia/&rdquo;in",
"      </span>",
"      situ&rdquo; follicular lymphoma &mdash; (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Intrafollicular neoplasia'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Primary intestinal follicular lymphoma &mdash; (see",
"      <a class=\"local\" href=\"#H99000111\">",
"       'Primary intestinal follicular lymphoma'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, primary cutaneous follicle center lymphoma is considered a distinct clinicopathologic entity. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Primary cutaneous follicle center lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of systemic follicular lymphoma is made based on the evaluation of a lymph node biopsy, typically in a patient with a history of waxing and waning lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15\">",
"     15",
"    </a>",
"    ]. Bone marrow examination is an important component of staging, but is not a reliable means of primary diagnosis.",
"   </p>",
"   <p>",
"    In classic cases, the histologic appearance of FL is so characteristic that it is one of the few forms of non-Hodgkin lymphoma that pathologists can diagnose based on morphology alone. Typically, the tumor has a distinctly nodular growth pattern and is comprised of a mixture of centrocytes and centroblasts (",
"    <a class=\"graphic graphic_picture graphicRef85888 \" href=\"UTD.htm?8/12/8394\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85890 \" href=\"UTD.htm?11/27/11706\">",
"     picture 8A",
"    </a>",
"    ). Mitoses and apoptotic cells, which are common in reactive follicles, are infrequently seen.",
"   </p>",
"   <p>",
"    However, FL has many less common morphologic variants, and sometimes lymph nodes are only partially involved. Also, on rare occasions, FL has an entirely diffuse growth pattern. In these situations, the diagnosis is based on a combination of morphologic and immunophenotypic findings. The diagnosis can also be made by fine needle aspiration of involved lymph nodes, with the caveat that it does not allow for assessment of growth pattern, and grading is problematic. With this modality, immunophenotypic analysis (generally carried out by flow cytometry) plays a central role in establishing the diagnosis.",
"   </p>",
"   <p>",
"    Characteristically, the tumor cells express monotypic immunoglobulin light chain, CD20 (or CD19), CD10, and BCL-6, and are negative for CD5 and CD23. The vast majority (&gt;85 percent) of tumors express BCL-2 as a result of a t(14;18), which can be detected by fluorescence in situ hybridization (FISH) or by polymerase chain reaction (PCR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intrafollicular neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrafollicular",
"    <span class=\"nowrap\">",
"     neoplasia/\"in",
"    </span>",
"    situ\" FL is a pathologic diagnosis used to describe the identification of follicles, typically several in number, that have a high content of",
"    <em>",
"     BCL2",
"    </em>",
"    -rearrangement-positive B cells within a lymph node that otherwise lacks the diagnostic features of FL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15\">",
"     15",
"    </a>",
"    ]. Some patients with this finding will prove to have disseminated FL on further work-up; the intrafollicular component in such cases presumably represents early seeding of FL to a partially involved node. Other patients, however, will not have evidence of FL on further evaluation. Little is known about the natural history of this second group of patients. A retrospective analysis of 34 cases of in situ FL with a median follow-up of 41 months reported only one case of progression to disseminated FL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/51\">",
"     51",
"    </a>",
"    ]. It is possible that the",
"    <em>",
"     BCL2",
"    </em>",
"    -rearrangement-positive cells in such cases are a hyperplastic B cell clone that has acquired the t(14;18), but lacks the other unknown genetic or epigenetic lesions that are required for full-blown FL to arise; if true, such patients may not be at any higher risk of FL than other members of the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99000111\">",
"    <span class=\"h2\">",
"     Primary intestinal follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary intestinal FL is a clinical variant of FL confined to the intestine (usually duodenum) that typically presents as multiple small polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/15\">",
"     15",
"    </a>",
"    ]. Primary FL of the intestine is a rare entity described in small case series and diagnosed approximately once in every 3000 to 7000 gastroduodenoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/52-60\">",
"     52-60",
"    </a>",
"    ]. The largest case series described sheets of small lymphoid cells consistent with grade 1 or 2 FL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/52\">",
"     52",
"    </a>",
"    ]. Lymphoid infiltrates were located outside of the follicular structures and occupied at least some duodenal villi. Unlike in MALT lymphoma, marginal zone differentiation was not seen. The clinical presentation of primary intestinal FL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for FL includes other malignant and non-malignant causes of lymphadenopathy. A general approach to adults and children who present with lymphadenopathy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common pathologic entities that are difficult to differentiate from FL are reactive follicular hyperplasia, cutaneous follicle center cell lymphoma, T cell rich large B cell lymphoma, mantle cell lymphoma, and nodal marginal zone lymphoma (",
"    <a class=\"graphic graphic_table graphicRef86190 \" href=\"UTD.htm?31/54/32620\">",
"     table 1",
"    </a>",
"    ). The latter is particularly relevant with unusual FL variants that exhibit plasmacytic or &ldquo;monocytoid B cell&rdquo; differentiation. In addition the identification of histologic transformation to diffuse large B cell lymphoma is extremely important. The differential diagnosis and evaluation of peripheral adenopathy in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of patients presenting with primary intestinal FL includes benign and malignant growths of the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Reactive follicular hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL recapitulates the normal germinal centers of secondary lymphoid follicles seen in reactive follicular hyperplasia. As such, it can be difficult to distinguish these two entities morphologically. However, subtle differences may be noted. In reactive follicular hyperplasia, histology shows discrete follicles of varying sizes and shapes that are separated from one another by interfollicular regions rich in T cells within the lymph node cortex. By contrast, the neoplastic follicles of FL tend to show little variation in size and shape, and are typically found back-to-back with little interfollicular tissue, throughout the node (",
"    <a class=\"graphic graphic_picture graphicRef69885 \" href=\"UTD.htm?20/20/20805\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In both reactive follicular hyperplasia and FL, T cells and follicular dendritic cells are present; however, tingible body (debris-laden) macrophages are not typically observed in FL but are prominent in reactive follicular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the Ki-67+ fraction is generally lower in FL than in reactive follicles.",
"   </p>",
"   <p>",
"    Perhaps the most useful differentiating characteristic is that cytoplasmic staining for BCL-2 protein is strongly positive in almost all grade",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    FL tumors, but universally negative in reactive follicular hyperplasia (",
"    <a class=\"graphic graphic_picture graphicRef64808 \" href=\"UTD.htm?37/54/38761\">",
"     picture 12",
"    </a>",
"    ). However, a high fraction of cutaneous FL, childhood FL, and systemic grade III FL tumors do not express BCL-2. As such, the presence of cytoplasmic BCL-2 rules out reactive follicular hyperplasia, but its absence is not as straightforward to interpret.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Primary cutaneous follicle center lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FL often present with painless peripheral adenopathy. Extralymphatic tissues can be involved secondarily. In contrast, primary cutaneous lymphomas present in the skin and do not involve other tissues. Primary cutaneous lymphomas of germinal center B cell origin are classified separately as primary cutaneous follicle center lymphoma. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL is usually easily distinguished from mantle cell lymphoma (MCL) by the presence of a nodular growth pattern in FL. Rarely, FL has an entirely diffuse pattern of growth with cell morphology that resembles MCL. In such cases, immunophenotyping is needed to confirm the diagnosis of FL and exclude MCL and chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic lymphoma. MCLs with a predominantly mantle zone growth pattern may also take on a nodular appearance, but in contrast to FL, MCL tumor cells express cyclin D1 and CD5, and do not express BCL-6 or CD10. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     T cell rich large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cases of diffuse large B cell lymphoma (DLBCL) have some infiltrating reactive T cells and macrophages (histiocytes), but in some tumors these cells predominate. This is the co-called T cell or histiocyte-rich large B cell lymphoma. Upon initial evaluation, the infiltrating T cells may resemble the small tumor cells of FL, in which the neoplastic B cells are fewer in number and resemble large centroblasts. Once the T cell origin of the small cells is identified, such cases are best classified as T cell rich large B cell lymphoma, a variant of diffuse large B cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'T cell histiocyte rich large B cell lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marginal zone lymphomas (MZL), both splenic and extranodal, can demonstrate a partially nodular pattern of growth that may resemble FL. MZL can usually be differentiated from FL by immunophenotype since, unlike FL, MZL does not usually express CD10, BCL-2, or BCL-6. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic transformation of FL to a diffuse large B cell lymphoma (DLBCL) occurs in 10 to 70 percent of patients over time, and is associated with rapid progression of lymphadenopathy, infiltration of extranodal sites, development of systemic symptoms, elevated serum LDH, and often a poor prognosis.",
"   </p>",
"   <p>",
"    Histology can vary greatly in different sections of the same lymph node. As such, careful examination of the sampled lymph node is key to determining whether a component of DLBCL is present. Discordant histologic features suggest histologic transformation of a previously undiagnosed indolent lymphoma. As an example, a small B cell proliferation may be identified in the bone marrow in a patient with large B cell involvement in a lymph node. The detection of areas of DLBCL within the lymph node denotes transformation to an aggressive phase of disease. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of FL is quite variable. Some patients have waxing and waning disease for five years or more without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/61\">",
"     61",
"    </a>",
"    ]. Others with more disseminated disease and rapid tumor growth require treatment because massive nodal or organ enlargement leads to pain, lymphatic obstruction, or organ obstruction. The two best measures of outcome are the follicular lymphoma international prognostic index (FLIPI) and tumor grade [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognostic features that aid in the decision to initiate therapy have been proposed by the Groupe d-Etude des Lymphomes Folliculaires (GELF) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/63\">",
"     63",
"    </a>",
"    ] and the British National Lymphoma Investigation (BNLI) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/64\">",
"     64",
"    </a>",
"    ]. Our approach, described separately, incorporates factors of each. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675522#H19675522\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described above, a subset of cases will undergo histologic transformation to a more aggressive lymphoma. Patients with histologic transformation generally have a worse prognosis and require more aggressive therapy. Prognostic factors for patients with histologic transformation are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also increasing evidence that the quality and quantity of the reactive cell response to the FL tumor cells influences biological behavior and outcome. Specifically, multiple studies indicate that an immune response rich in T cells predicts a better outcome, whereas an immune response dominated by macrophages is associated with a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/65-68\">",
"     65-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75814042\">",
"    <span class=\"h2\">",
"     Follicular lymphoma IPI (FLIPI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Prognostic Index (IPI) is a prognostic tool that was originally developed in patients with clinically aggressive non-Hodgkin lymphoma (eg, diffuse large B cell lymphoma) and uses patient age, serum lactate dehydrogenase, performance status, stage, and number of extranodal disease sites to predict overall survival rates; its application to patients with FL has resulted in conflicting results, due in large part to a low number of patients with FL (approximately 10 percent) belonging to the higher risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This original IPI has been modified to create two prognostic tools for use in patients with FL: the original follicular lymphoma IPI (FLIPI) and the subsequent FLIPI2. The FLIPI is the main prognostic tool used for patients with FL. While the role of the FLIPI2 in clinical practice is unclear at this time, this system supports the prognostic value of these factors that were previously not part of the original FLIPI. These two prognostic tools are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548324\">",
"    <span class=\"h3\">",
"     Original FLIPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Follicular Lymphoma International Prognostic Index (FLIPI) was devised based on an international study of long-term survival in 4167 patients with FL diagnosed between 1985 and 1992 (",
"    <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/16\">",
"     16",
"    </a>",
"    ]. Five adverse prognostic factors were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60 years",
"     </li>",
"     <li>",
"      Ann Arbor stage III or IV (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemoglobin level &lt;12.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Number of involved nodal areas &gt;4 (",
"      <a class=\"graphic graphic_figure graphicRef55422 \" href=\"UTD.htm?41/2/42021\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum lactate dehydrogenase level greater than the upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following three risk groups and their corresponding five- and 10-year overall survival rates in the pre-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    era were, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (zero to one adverse factors) &mdash; 91 and 71 percent; relative risk (RR) of death: 1.0 (comparison group)",
"     </li>",
"     <li>",
"      Intermediate risk (two adverse factors) &mdash; 78 and 51 percent. RR 2.3 (95% CI 1.9-2.8)",
"     </li>",
"     <li>",
"      High risk (three or more adverse factors) &mdash; 52 and 36 percent. RR 4.3 (95% CI 3.5-5.3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to standard chemotherapy has resulted in significant improvements in the overall survival rates of CD-20 positive tumors. Subsequent studies indicate the usefulness of the FLIPI in assessing prognosis in patients with FL treated with rituximab-containing therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective observational study of 2192 patients diagnosed with FL between 2004 and 2007 and managed by academic or community practices identified low risk, intermediate risk, and high risk FLIPI scores in 35, 30, and 35 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/72\">",
"     72",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    was included in the initial management of the majority (68 percent), while a minority was managed initially with watchful waiting (17 percent) or non-rituximab containing therapy (15 percent). The following were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three FLIPI risk groups differed significantly from each other in their estimates for overall survival, progression-free survival, and time to next therapy. As an example, when compared with low risk disease, survival was significantly shorter for patients with intermediate (HR 2.37; 95% CI 1.64-3.41) or high (HR 6.17; 95% CI 4.47-8.53) risk disease.",
"     </li>",
"     <li>",
"      This scoring system retained its prognostic value in analyses of subsets identified by initial treatment strategy.",
"     </li>",
"     <li>",
"      At a median follow-up of 58 months, median overall survival had not been reached. Estimated survival rates at two years were 98, 94, and 87 percent for patients with low, intermediate, and high risk FLIPI, respectively.",
"     </li>",
"     <li>",
"      Median progression-free survival was 84, 70, and 42 months for low, intermediate, and poor risk disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support the prognostic value of the FLIPI in patients treated in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    era.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548331\">",
"    <span class=\"h3\">",
"     FLIPI2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Follicular Lymphoma International Prognostic Index 2 (FLIPI2) was developed using prospective data from 942 patients receiving treatment for newly diagnosed FL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/73\">",
"     73",
"    </a>",
"    ]. The FLIPI2 evaluates five parameters, some of which overlap of the original FLIPI:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60 years",
"     </li>",
"     <li>",
"      Bone marrow involvement",
"     </li>",
"     <li>",
"      Hemoglobin level &lt;12.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Greatest diameter of the largest involved node more than 6 cm",
"     </li>",
"     <li>",
"      Serum beta-2 microglobulin level greater than the upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three-year progression-free survival rates of patients with low (zero factors), intermediate (1 to 2 factors), or high (3 to 5 factors) FLIPI2 scores were 91, 69, and 51 percent, respectively. Corresponding three-year survival rates were 99, 96, and 84 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Tumor grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL tumors are graded on a scale from I to III, and this grade appears to have some prognostic value. There has been poor consensus of pathologists on the determination of the grade of FL. However, the most commonly used grading system is presented above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Grade'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The minor differences in clinical behavior and response to treatment have not supported a different treatment approach toward grade I versus grade II FL. Thus, although the grading system remains in place, for clinical decision making, grade I and II FL should be approached similarly and considered to be clinically indolent lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/25\">",
"     25",
"    </a>",
"    ]. Although controversial, differences in molecular genetics as well as clinical behavior suggest that FL grade IIIa may be an indolent disease and IIIb a more aggressive one [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/29,74-76\">",
"     29,74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follicular lymphoma grade IIIb is synonymous with what is often referred to as follicular large cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast to lower grade FLs, this histologic variant has a lesser tendency to involve the bone marrow or peripheral blood and often presents with larger lymphoid masses. Although the follicular architecture is preserved, the clinical presentation, behavior, and outcome with treatment more closely approximates that of diffuse large B cell lymphoma (DLBCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. In contrast to DLBCL, the relapse rate of FL grade IIIb is higher following combination chemotherapy, but the survival is longer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. The diagnosis of DLBCL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75815126\">",
"    <span class=\"h2\">",
"     Microenvironment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies point to the possibility that variation in the cellular microenvironment influences the overall prognosis in a number of malignancies, including FL. This association suggests that FL is an immunologically functional disease in which an interaction between the tumor cells and the microenvironment has a strong bearing on the overall clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of initial findings concerning the interactions between microenvironmental factors, treatment, and prognosis in FL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/66,67,83-89\">",
"     66,67,83-89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using gene expression profiling on tumor specimens obtained from 191 previously untreated patients with FL, the length of survival correlated with the molecular features of nonmalignant immune cells (eg, T cells,",
"      <span class=\"nowrap\">",
"       monocytes/macrophages,",
"      </span>",
"      dendritic cells) present in the tumor at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/66,83\">",
"       66,83",
"      </a>",
"      ]. A two-signature model based upon these results and divided into quartiles yielded median survivals of 14, 11, 11, and 4 years, respectively. These survival values were independent of the clinical variables included in the International Prognostic Index (IPI). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"       \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of 139 patients with FL in whom flow cytometry had been performed on an involved lymph node, higher CD8+ T cell levels correlated with longer overall survival and disease-specific survival [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/84\">",
"       84",
"      </a>",
"      ]. Patients who had not required treatment within six months of diagnosis had significantly more CD8+ T cells than those who required treatment. The statistical significance of CD8+ T cells was independent of the Follicular Lymphoma International Prognostic Index (FLIPI). (See",
"      <a class=\"local\" href=\"#H75814042\">",
"       'Follicular lymphoma IPI (FLIPI)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among 97 and 37 patients with FL studied at diagnosis or first relapse, respectively, higher percentages of FOXP3+ regulatory T (Treg) cells correlated directly with longer five-year overall survival, while very low numbers were associated with refractory disease or histologic transformation to diffuse large B cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/67\">",
"       67",
"      </a>",
"      ]. The prognostic significance of Treg cell numbers was independent of the FLIPI, and might be explained by a direct inhibitory effect on the neoplastic B cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Major challenges in this field include the limited reproducibility of the techniques used, variability of antibodies used, and interobserver variability in scoring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/46/25322/abstract/90\">",
"     90",
"    </a>",
"    ]. Increased reliance on small samples (eg, needle core biopsies) for diagnosis may also negatively affect the predictive value of these analyses. Ongoing studies will help to expand upon and clarify these preliminary results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=see_link\">",
"       \"Patient information: Follicular lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular lymphoma (FL) is the second most common lymphoma in the United States and Western Europe. It most frequently presents in middle-aged Caucasians. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with FL usually present with painless peripheral adenopathy, often with a long history of waxing and waning lymph node enlargement. Widespread disseminated disease is usually present at baseline, but patients are typically asymptomatic aside from their lymphadenopathy. There are no characteristic laboratory abnormalities and, despite the large tumor burden, the majority has a normal serum lactate dehydrogenase (LDH) level. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, FL arises in children or adolescents. A substantial proportion of these tumors appear to be biologically distinct from typical adult FL. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On histology, a nodular growth pattern and cell morphology consisting of a mixture of centrocytes and centroblasts is characteristic. The proportion of centroblasts found in the sample determines the tumor grade, which has therapeutic implications. Involvement of the bone marrow and peripheral blood is often seen but may not be prominent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Morphologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tumor cells express monotypic immunoglobulin light chain, CD20 (or CD19), CD10, and BCL-6 and are negative for CD5 and CD23. The vast majority (&gt;85 percent) of tumors express BCL-2. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molecular genetics can confirm the presence of immunoglobulin gene rearrangements and the t(14;18) involving",
"      <em>",
"       BCL2",
"      </em>",
"      , which is not specific for FL. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Molecular genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of FL is primarily made based upon the evaluation of a lymph node biopsy in a patient who has had a history of waxing and waning lymphadenopathy. In classic cases, the histologic appearance of FL is so characteristic that it is one of the few forms of non-Hodgkin lymphoma that pathologists can diagnose based on morphology alone. Typically, the tumor has a distinctly nodular growth pattern and is comprised of a mixture of centrocytes and centroblasts (",
"      <a class=\"graphic graphic_picture graphicRef85888 \" href=\"UTD.htm?8/12/8394\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef85890 \" href=\"UTD.htm?11/27/11706\">",
"       picture 8A",
"      </a>",
"      ). However, FL has many less common morphologic variants, and sometimes lymph nodes are only partially involved. In these situations, the diagnosis is based on a combination of morphologic and immunophenotypic findings. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for FL is comprised of other malignant and non-malignant diseases that result in lymphadenopathy (",
"      <a class=\"graphic graphic_table graphicRef86190 \" href=\"UTD.htm?31/54/32620\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"       \"Evaluation of peripheral lymphadenopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The course of FL is quite variable. The two best measures of outcome are the Follicular Lymphoma International Prognostic Index (FLIPI) (",
"      <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"       table 2",
"      </a>",
"      ) and tumor grade. There is also increasing evidence that the immune response to the tumor influences clinical behavior and outcome. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/1\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/2\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/3\">",
"      Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002; 99:4265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/4\">",
"      Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/5\">",
"      A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/6\">",
"      Pinto A, Hutchison RE, Grant LH, et al. Follicular lymphomas in pediatric patients. Mod Pathol 1990; 3:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/7\">",
"      Winberg CD, Nathwani BN, Bearman RM, Rappaport H. Follicular (nodular) lymphoma during the first two decades of life: a clinicopathologic study of 12 patients. Cancer 1981; 48:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/8\">",
"      Frizzera G, Murphy SB. Follicular (nodular) lymphoma in childhood: a rare clinical-pathological entity. Report of eight cases from four cancer centers. Cancer 1979; 44:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/9\">",
"      Lorsbach RB, Shay-Seymore D, Moore J, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002; 99:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/10\">",
"      Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010; 42:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/11\">",
"      Skibola CF, Bracci PM, Halperin E, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet 2009; 41:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/12\">",
"      Goldin LR, Bj&ouml;rkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/13\">",
"      Cossman J, Neckers LM, Hsu S, et al. Low-grade lymphomas. Expression of developmentally regulated B-cell antigens. Am J Pathol 1984; 115:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/14\">",
"      Jaffe ES, Shevach EM, Frank MM, et al. Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med 1974; 290:813.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/16\">",
"      Solal-C&eacute;ligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/17\">",
"      Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/18\">",
"      Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/19\">",
"      Fern&aacute;ndez de Larrea C, Mart&iacute;nez-Pozo A, Mercadal S, et al. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol 2011; 153:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/20\">",
"      Louissaint A Jr, Ackerman AM, Dias-Santagata D, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood 2012; 120:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/21\">",
"      Stein H, Gerdes J, Mason DY. The normal and malignant germinal centre. Clin Haematol 1982; 11:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/22\">",
"      Stein H, Lennert K, Feller AC, Mason DY. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/23\">",
"      Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol 1984; 117:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/24\">",
"      Nathwani BN, Anderson JR, Armitage JO, et al. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. Hum Pathol 1999; 30:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/25\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/26\">",
"      Mann RB, Berard CW. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1983; 1:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/27\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/28\">",
"      Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99:3806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/29\">",
"      Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/30\">",
"      Canioni D, Brice P, Lepage E, et al. Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires. Br J Haematol 2004; 126:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/31\">",
"      Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/32\">",
"      Karube K, Guo Y, Suzumiya J, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 2007; 109:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/33\">",
"      Barry TS, Jaffe ES, Kingma DW, et al. CD5+ follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol 2002; 118:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/34\">",
"      Flenghi L, Bigerna B, Fizzotti M, et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol 1996; 148:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/35\">",
"      Pittaluga S, Ayoubi TA, Wlodarska I, et al. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. J Pathol 1996; 179:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/36\">",
"      Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/37\">",
"      Cleary ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell 1986; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/38\">",
"      Bahler DW, Campbell MJ, Hart S, et al. Ig VH gene expression among human follicular lymphomas. Blood 1991; 78:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/39\">",
"      Bloomfield CD, Arthur DC, Frizzera G, et al. Nonrandom chromosome abnormalities in lymphoma. Cancer Res 1983; 43:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/40\">",
"      Rowley JD. Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation. J Clin Oncol 1988; 6:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/41\">",
"      Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/42\">",
"      Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/43\">",
"      Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009; 114:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/44\">",
"      Gribben JG, Freedman As, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78:3275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/45\">",
"      Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 1988; 318:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/46\">",
"      Tang SC, Visser L, Hepperle B, et al. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol 1994; 12:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/47\">",
"      Yunis JJ. bcl-2 oncogene rearrangement in follicular and diffuse large-cell and mixed-cell lymphoma. Cancer Cells 1989; 7:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/48\">",
"      Yunis JJ, Mayer MG, Arnesen MA, et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/49\">",
"      D&iacute;az-Alderete A, Doval A, Camacho F, et al. Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features. Leuk Lymphoma 2008; 49:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/50\">",
"      Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/51\">",
"      Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011; 118:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/52\">",
"      Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 2011; 29:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/53\">",
"      Yoshino T, Miyake K, Ichimura K, et al. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000; 24:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/54\">",
"      Poggi MM, Cong PJ, Coleman CN, Jaffe ES. Low-grade follicular lymphoma of the small intestine. J Clin Gastroenterol 2002; 34:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/55\">",
"      Shia J, Teruya-Feldstein J, Pan D, et al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol 2002; 26:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/56\">",
"      Bende RJ, Smit LA, Bossenbroek JG, et al. Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells. Am J Pathol 2003; 162:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/57\">",
"      Damaj G, Verkarre V, Delmer A, et al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol 2003; 14:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/58\">",
"      Sato Y, Ichimura K, Tanaka T, et al. Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol 2008; 61:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/59\">",
"      Yamamoto S, Nakase H, Yamashita K, et al. Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol 2010; 45:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/60\">",
"      Mori M, Kobayashi Y, Maeshima AM, et al. The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma. Ann Oncol 2010; 21:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/61\">",
"      Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/62\">",
"      Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol 2010; 28:2902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/63\">",
"      Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/64\">",
"      Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/65\">",
"      Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/66\">",
"      Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/67\">",
"      Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/68\">",
"      Byers RJ, Sakhinia E, Joseph P, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008; 111:4764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/69\">",
"      Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999; 17:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/70\">",
"      L&oacute;pez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/71\">",
"      Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/72\">",
"      Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 2013; 24:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/73\">",
"      Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27:4555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/74\">",
"      Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/75\">",
"      Shustik J, Quinn M, Connors JM, et al. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 2011; 22:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/76\">",
"      Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 2012; 156:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/77\">",
"      Anderson JR, Vose JM, Bierman PJ, et al. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993; 11:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/78\">",
"      Rodriguez J, McLaughlin P, Hagemeister FB, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/79\">",
"      Chau I, Jones R, Cunningham D, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/80\">",
"      Ha CS, Kong JS, McLaughlin P, et al. Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2003; 57:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/81\">",
"      Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/82\">",
"      Alvaro T, Lejeune M, Salvad&oacute; MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24:5350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/83\">",
"      K&uuml;ppers R. Prognosis in follicular lymphoma--it's in the microenvironment. N Engl J Med 2004; 351:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/84\">",
"      Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/85\">",
"      Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24:5052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/86\">",
"      Klapper W, Hoster E, R&ouml;lver L, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007; 25:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/87\">",
"      Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/88\">",
"      Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13:5784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/89\">",
"      Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/46/25322/abstract/90\">",
"      de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25:805.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4699 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25322=[""].join("\n");
var outline_f24_46_25322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Morphologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Growth pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cell morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Grade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Blood and bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Immunoglobulin genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cytogenetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intrafollicular neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99000111\">",
"      Primary intestinal follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Reactive follicular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      T cell rich large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75814042\">",
"      Follicular lymphoma IPI (FLIPI)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H548324\">",
"      - Original FLIPI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H548331\">",
"      - FLIPI2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Tumor grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75815126\">",
"      Microenvironment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4699|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/55/24437\" title=\"figure 1\">",
"      Flow cytometry FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/2/42021\" title=\"figure 2\">",
"      Lymph node regions lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4699|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/12/8394\" title=\"picture 1\">",
"      Packed nodules FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/20/20805\" title=\"picture 2\">",
"      Reactive node vs FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/34/31268\" title=\"picture 3\">",
"      Transformation FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/56/21386\" title=\"picture 4\">",
"      FL grade 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/49/16154\" title=\"picture 5\">",
"      FL grade 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/56/26502\" title=\"picture 6\">",
"      Follicular small cleaved NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/12/12487\" title=\"picture 7\">",
"      Follicular large cell NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/27/11706\" title=\"picture 8A\">",
"      FL grade 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/49/35606\" title=\"picture 8B\">",
"      Follicular mixed NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/28/30153\" title=\"picture 9\">",
"      FL paratrabecular lymphoid infiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/54/24416\" title=\"picture 10\">",
"      FL with leukemic cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/63/25594\" title=\"picture 11\">",
"      FL immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/54/38761\" title=\"picture 12\">",
"      Bcl 2 staining in FL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4699|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/54/32620\" title=\"table 1\">",
"      DDx FL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/23/37243\" title=\"table 2\">",
"      Follic lymphoma int prog index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 3\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=related_link\">",
"      Epidemiology, clinical features, and types of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=related_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_46_25323="Assessment for allo-HCT eligibility";
var content_f24_46_25323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment for allogeneic hematopoietic cell transplantation eligibility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Detailed history and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Including Karnofsky performance status and dental examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Laboratory studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Complete blood count with differential; chemistries with liver and renal function and electrolytes; pregnancy test; ABO typing; serology for HIV, hepatitis B, hepatitis C, herpes simplex and varicella, cytomegalovirus, Epstein Barr virus, and human T-lymphotropic virus type I and II; urine for micro-analysis and macro-analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow aspiration and biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chest radiograph, an electrocardiogram, and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary function test, including DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disease-specific restaging studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Donor search",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MUGA: multiple gated cardiac blood pool imaging; DLCO: diffusing capacity of the lungs for carbon monoxide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25323=[""].join("\n");
var outline_f24_46_25323=null;
var title_f24_46_25324="NCCN criteria for palliative care assessment";
var content_f24_46_25324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCCN criteria for palliative care assessment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient characteristics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Social circumstances or issues related to anticipatory bereavement",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Limited options for treatment",
"       </td>",
"       <td>",
"        Limited access to care",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        High risk of poor pain control or refractory pain. Risk factors include:",
"        <ul>",
"         <li>",
"          Neuropathic pain",
"         </li>",
"         <li>",
"          Incident or breakthrough pain",
"         </li>",
"         <li>",
"          Rapid escalation of opioid dose",
"         </li>",
"         <li>",
"          History of substance (drug, alcohol) abuse",
"         </li>",
"         <li>",
"          Impaired cognition",
"         </li>",
"         <li>",
"          Psychosocial/family distress",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Familial factors, including:",
"        <ul>",
"         <li>",
"          Limitations of the family/caregiver",
"         </li>",
"         <li>",
"          Inadequate family support",
"         </li>",
"         <li>",
"          Family discord",
"         </li>",
"         <li>",
"          History of intensely dependent relationship(s)",
"         </li>",
"         <li>",
"          Parental concerns regarding care of dependents",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        High symptom burden or distress score",
"       </td>",
"       <td>",
"        Financial limitations",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Intensive care unit admission with multiple complications or need for prolonged ventilator support",
"       </td>",
"       <td>",
"        Unresolved grief or multiple prior losses",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Physical symptoms other than pain that are refractory to conventional management",
"       </td>",
"       <td>",
"        Spiritual or existential crisis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Cognitive impairment",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Severe or multiple comorbid conditions",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Communication barriers related to language, literacy, or physical issues",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Request for hastened death",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to engage in advance care planning and care plan",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: NCCN Guidelines Version 2.2012. Palliative Care.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25324=[""].join("\n");
var outline_f24_46_25324=null;
var title_f24_46_25325="PO4 induces hyperparathyroidism";
var content_f24_46_25325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phosphate and secondary hyperparathyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 210px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypothetical model for the development of secondary hyperparathyroidism in advancing chronic renal failure. Each decrement in GFR promotes phosphate retention and a small reduction in the plasma Ca2+ concentration. The latter change, plus a possible decline in calcitriol levels, stimulates PTH secretion which, at least initially, is able to return the plasma Ca2+ and phosphate concentrations to normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Slatopolsky, E, Bricker, NS, Kidney Int 1973; 4:14. Reprinted by permission from Kidney International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25325=[""].join("\n");
var outline_f24_46_25325=null;
var title_f24_46_25326="Superior sulcus PET";
var content_f24_46_25326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior sulcus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal PET scan shows the glucose avid right apical tumor as well as a lower rib metastasis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25326=[""].join("\n");
var outline_f24_46_25326=null;
var title_f24_46_25327="Management of knee dislocation";
var content_f24_46_25327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Management of knee (tibiofemoral) dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 432px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_46_25327=[""].join("\n");
var outline_f24_46_25327=null;
